{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:49:59Z","timestamp":1794329399024,"version":"4.9.0"},"reference-count":575,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02954-4","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:05:53Z","timestamp":1790168753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation"],"prefix":"10.1038","volume":"11","author":[{"given":"Cristina","family":"Camps-Fajol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Minguill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Surrall\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2954_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","volume":"31","author":"T Dobzhansky","year":"1946","unstructured":"Dobzhansky, T. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics 31, 269\u2013290 (1946).","journal-title":"Genetics"},{"key":"2954_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin","year":"2005","unstructured":"Kaelin, W. G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689\u2013698 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"2954_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1086\/279847","volume":"56","author":"CB Bridges","year":"1922","unstructured":"Bridges, C. B. The origin of variations in sexual and sex -limited characters. Am. Nat. 56, 51\u201363 (1922).","journal-title":"Am. Nat."},{"key":"2954_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1534\/g3.117.042317","volume":"7","author":"C Zimmermann","year":"2017","unstructured":"Zimmermann, C. et al. Mapping the synthetic dosage lethality network of CDK1\/CDC28. G3 7, 1753\u20131766 (2017).","journal-title":"G3"},{"key":"2954_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006942","volume":"13","author":"CJ Cairney","year":"2017","unstructured":"Cairney, C. J. et al. A \u2018synthetic-sickness\u2019 screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genet. 13, e1006942 (2017).","journal-title":"PLoS Genet."},{"key":"2954_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.1150021","volume":"320","author":"ME Hillenmeyer","year":"2008","unstructured":"Hillenmeyer, M. E. et al. The chemical genomic portrait of yeast: Uncovering a phenotype for all genes. Science 320, 362\u2013365 (2008).","journal-title":"Science"},{"key":"2954_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143765","volume":"131","author":"KJ Metcalf","year":"2021","unstructured":"Metcalf, K. J., Alazzeh, A., Werb, Z. & Weaver, V. M. Leveraging microenvironmental synthetic lethalities to treat cancer. J. Clin. Invest. 131, e143765 (2021).","journal-title":"J. Clin. Invest."},{"key":"2954_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg.2017.47","volume":"18","author":"NJ O\u2019Neil","year":"2017","unstructured":"O\u2019Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18, 613\u2013623 (2017).","journal-title":"Nat. Rev. Genet."},{"key":"2954_CR9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/cancers13071591","volume":"13","author":"L Castells-Roca","year":"2021","unstructured":"Castells-Roca, L., Tejero, E., Rodr\u00edguez-Santiago, B. & Surrall\u00e9s, J. Crispr screens in synthetic lethality and combinatorial therapies for cancer. Cancers 13, 1591 (2021).","journal-title":"Cancers"},{"key":"2954_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064\u20131068 (1997).","journal-title":"Science"},{"key":"2954_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10555-020-09903-9","volume":"39","author":"A Ghimessy","year":"2020","unstructured":"Ghimessy, A. et al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev. 39, 1159\u20131177 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"2954_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-020-00956-5","volume":"13","author":"W Topatana","year":"2020","unstructured":"Topatana, W. et al. Advances in synthetic lethality for cancer therapy: Cellular mechanism and clinical translation. J. Hematol. Oncol. 13, 118 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2954_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"2954_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jcp.25048","volume":"231","author":"WJ Cannan","year":"2016","unstructured":"Cannan, W. J. & Pederson, D. S. Mechanisms and consequences of double-strand DNA break formation in chromatin. J. Cell. Physiol. 231, 3\u201314 (2016).","journal-title":"J. Cell. Physiol."},{"key":"2954_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang, H. H. Y., Pannunzio, N. R., Adachi, N. & Lieber, M. R. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat. Rev. Mol. Cell Biol. 18, 495\u2013506 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2954_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00412-017-0658-1","volume":"127","author":"L Ranjha","year":"2018","unstructured":"Ranjha, L., Howard, S. M. & Cejka, P. Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. Chromosoma 127, 187\u2013214 (2018).","journal-title":"Chromosoma"},{"key":"2954_CR17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41594-023-01065-w","volume":"30","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. In vivo tracking of functionally tagged Rad51 unveils a robust strategy of homology search. Nat. Struct. Mol. Biol. 30, 1582\u20131591 (2023).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2954_CR18","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1021\/cr068207j","volume":"107","author":"Y Jung","year":"2007","unstructured":"Jung, Y. & Lippard, S. J. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107, 1387\u20131407 (2007).","journal-title":"Chem. Rev."},{"key":"2954_CR19","doi-asserted-by":"publisher","first-page":"11704","DOI":"10.1158\/0008-5472.CAN-05-1214","volume":"65","author":"K Nojima","year":"2005","unstructured":"Nojima, K. et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 65, 11704\u201311711 (2005).","journal-title":"Cancer Res."},{"key":"2954_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.molcel.2009.08.014","volume":"35","author":"M Ben-Yehoyada","year":"2009","unstructured":"Ben-Yehoyada, M. et al. Checkpoint signaling from a single DNA interstrand crosslink. Mol. Cell 35, 704\u2013715 (2009).","journal-title":"Mol. Cell"},{"key":"2954_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.gde.2015.07.002","volume":"33","author":"M Bogliolo","year":"2015","unstructured":"Bogliolo, M. & Surrall\u00e9s, J. Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics. Curr. Opin. Genet. Dev. 33, 32\u201340 (2015).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2954_CR22","doi-asserted-by":"publisher","first-page":"102137","DOI":"10.1016\/j.arr.2023.102137","volume":"92","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. DNA damage response, a double-edged sword for vascular aging. Ageing Res. Rev. 92, 102137 (2023).","journal-title":"Ageing Res. Rev."},{"key":"2954_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","volume":"7","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi, N. Y. L., Pham, M. M., Tan, D. S. P. & Yap, T. A. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer 7, 930\u2013957 (2021).","journal-title":"Trends Cancer"},{"key":"2954_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.dnarep.2007.12.008","volume":"7","author":"HL Klein","year":"2008","unstructured":"Klein, H. L. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair 7, 686\u2013693 (2008).","journal-title":"DNA Repair"},{"key":"2954_CR25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/bjc.2012.483","volume":"107","author":"J Iqbal","year":"2012","unstructured":"Iqbal, J. et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 107, 2005\u20132009 (2012).","journal-title":"Br. J. Cancer"},{"key":"2954_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.juro.2010.03.044","volume":"184","author":"J Yang","year":"2010","unstructured":"Yang, J. et al. XPC epigenetic silence coupled With p53 alteration has a significant impact on bladder cancer outcome. J. Urol. 184, 336\u2013343 (2010).","journal-title":"J. Urol."},{"key":"2954_CR27","first-page":"2453","volume":"29","author":"T Nikolova","year":"2009","unstructured":"Nikolova, T., Christmann, M. & Kaina, B. FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res. 29, 2453\u20132459 (2009).","journal-title":"Anticancer Res."},{"key":"2954_CR28","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.18632\/oncotarget.2083","volume":"5","author":"KA Bridges","year":"2014","unstructured":"Bridges, K. A. et al. Niraparib (MK-4827), a novel poly(ADP-ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget 5, 5076\u20135086 (2014).","journal-title":"Oncotarget"},{"key":"2954_CR29","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1158\/0008-5472.CAN-09-3573","volume":"70","author":"MA Morgan","year":"2010","unstructured":"Morgan, M. A. et al. Mechanism of radiosensitization by the Chk1\/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70, 4972\u20134981 (2010).","journal-title":"Cancer Res."},{"key":"2954_CR30","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","volume":"17","author":"KA Bridges","year":"2011","unstructured":"Bridges, K. A. et al. MK-1775, a novel wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res. 17, 5638\u20135648 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR31","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/1535-7163.MCT-09-1027","volume":"9","author":"DA L\u00f6ser","year":"2010","unstructured":"L\u00f6ser, D. A. et al. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol. Cancer Ther. 9, 1775\u20131787 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR32","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-19-3373","volume":"26","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Wee1 kinase inhibitor AZD1775 effectively sensitizes esophageal cancer to radiotherapy. Clin. Cancer Res. 26, 3740\u20133750 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR33","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland, K. C. et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587\u201313598 (2016).","journal-title":"Oncotarget"},{"key":"2954_CR34","doi-asserted-by":"publisher","first-page":"648687","DOI":"10.3389\/fonc.2021.648687","volume":"11","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications. Front. Oncol. 11, 648687 (2021).","journal-title":"Front. Oncol."},{"key":"2954_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai, L. et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell 39, 989\u2013998.e5 (2021).","journal-title":"Cancer Cell"},{"key":"2954_CR36","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1158\/2767-9764.CRC-23-0051","volume":"3","author":"M Moutafi","year":"2023","unstructured":"Moutafi, M. et al. Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer. Cancer Res. Commun. 3, 1514\u20131523 (2023).","journal-title":"Cancer Res. Commun."},{"key":"2954_CR37","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"2954_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"2954_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly, M. B. et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 19, 77\u2013102 (2021).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2954_CR40","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1002\/jcp.27464","volume":"234","author":"M Mahdavi","year":"2019","unstructured":"Mahdavi, M. et al. Hereditary breast cancer; Genetic penetrance and current status with BRCA. J. Cell. Physiol. 234, 5741\u20135750 (2019).","journal-title":"J. Cell. Physiol."},{"key":"2954_CR41","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1038\/onc.2012.257","volume":"32","author":"MA Serrano","year":"2013","unstructured":"Serrano, M. A. et al. DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. Oncogene 32, 2452\u20132462 (2013).","journal-title":"Oncogene"},{"key":"2954_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0115-9","volume":"5","author":"A Li","year":"2019","unstructured":"Li, A. et al. Homologous recombination DNA repair defects in PALB2-associated breast cancers. npj Breast Cancer 5, 23 (2019).","journal-title":"npj Breast Cancer"},{"key":"2954_CR43","first-page":"4842","volume":"61","author":"ME Moynahan","year":"2001","unstructured":"Moynahan, M. E., Cui, T. Y. & Jasin, M. Homology-directed DNA repair, mitomycin-C resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61, 4842\u20134850 (2001).","journal-title":"Cancer Res."},{"key":"2954_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/cancers8040041","volume":"8","author":"R Dok","year":"2016","unstructured":"Dok, R. & Nuyts, S. HPV positive head and neck cancers: Molecular pathogenesis and evolving treatment strategies. Cancers 8, 41 (2016).","journal-title":"Cancers"},{"key":"2954_CR45","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"2954_CR46","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15, 1152\u20131158 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2954_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10741-9","volume":"10","author":"MC Caron","year":"2019","unstructured":"Caron, M. C. et al. Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat. Commun. 10, 2954 (2019).","journal-title":"Nat. Commun."},{"key":"2954_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molcel.2008.08.009","volume":"32","author":"H Kleine","year":"2008","unstructured":"Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57\u201369 (2008).","journal-title":"Mol. Cell"},{"key":"2954_CR49","doi-asserted-by":"publisher","first-page":"801200","DOI":"10.3389\/fcell.2021.801200","volume":"9","author":"IA Richard","year":"2022","unstructured":"Richard, I. A., Burgess, J. T., O\u2019Byrne, K. J. & Bolderson, E. Beyond PARP1: the potential of other members of the poly (ADP-Ribose) polymerase family in DNA repair and cancer therapeutics. Front. Cell Dev. Biol. 9, 801200 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"2954_CR50","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1242\/jcs.114.20.3771","volume":"114","author":"D D\u2019Amours","year":"2001","unstructured":"D\u2019Amours, D., Sallmann, F. R., Dixit, V. M. & Poirier, G. G. Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: Implications for apoptosis. J. Cell Sci. 114, 3771\u20133778 (2001).","journal-title":"J. Cell Sci."},{"key":"2954_CR51","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610\u2013621 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2954_CR52","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.1216338","volume":"336","author":"MF Langelier","year":"2012","unstructured":"Langelier, M. F., Planck, J. L., Roy, S. & Pascal, J. M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336, 728\u2013732 (2012).","journal-title":"Science"},{"key":"2954_CR53","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1093\/nar\/gku474","volume":"42","author":"MF Langelier","year":"2014","unstructured":"Langelier, M. F., Riccio, A. A. & Pascal, J. M. PARP-2 and PARP-3 are selectively activated by 5\u2019 phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res. 42, 7762\u20137775 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2954_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/nar\/gki190","volume":"33","author":"S Okano","year":"2005","unstructured":"Okano, S., Lan, L., Tomkinson, A. E. & Yasui, A. Translocation of XRCC1 and DNA ligase III\u03b1 from centrosomes to chromosomes in response to DNA damage in mitotic human cells. Nucleic Acids Res. 33, 422\u2013429 (2005).","journal-title":"Nucleic Acids Res."},{"key":"2954_CR55","doi-asserted-by":"publisher","first-page":"12834","DOI":"10.1093\/nar\/gkx1047","volume":"45","author":"L Liu","year":"2017","unstructured":"Liu, L. et al. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1. Nucleic Acids Res. 45, 12834\u201312847 (2017).","journal-title":"Nucleic Acids Res."},{"key":"2954_CR56","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.molcel.2018.08.045","volume":"71","author":"N van Wietmarschen","year":"2018","unstructured":"van Wietmarschen, N. & Nussenzweig, A. Mechanism for synthetic lethality in BRCA-deficient cancers: no longer lagging behind. Mol. Cell 71, 877\u2013878 (2018).","journal-title":"Mol. Cell"},{"key":"2954_CR57","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72, 5588\u20135599 (2012).","journal-title":"Cancer Res"},{"key":"2954_CR58","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza, A. et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature 559, 279\u2013284 (2018).","journal-title":"Nature"},{"key":"2954_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/cas.13530","volume":"109","author":"S Sunada","year":"2018","unstructured":"Sunada, S., Nakanishi, A. & Miki, Y. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1\/2-mutated cancer. Cancer Sci. 109, 893\u2013899 (2018).","journal-title":"Cancer Sci."},{"key":"2954_CR60","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/ijms23031701","volume":"23","author":"W Choi","year":"2022","unstructured":"Choi, W. & Lee, E. S. Therapeutic targeting of DNA damage response in cancer. Int. J. Mol. Sci. 23, 1701 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2954_CR61","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","volume":"628","author":"M Petropoulos","year":"2024","unstructured":"Petropoulos, M. et al. Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors. Nature 628, 433\u2013441 (2024).","journal-title":"Nature"},{"key":"2954_CR62","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-20-1602","volume":"81","author":"NJ Panzarino","year":"2021","unstructured":"Panzarino, N. J. et al. Replication gaps underlie BRCA deficiency and therapy response. Cancer Res. 81, 1388\u20131397 (2021).","journal-title":"Cancer Res."},{"key":"2954_CR63","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong, K. et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol. Cell 81, 3128\u20133144.e7 (2021).","journal-title":"Mol. Cell"},{"key":"2954_CR64","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"J Murai","year":"2014","unstructured":"Murai, J. et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13, 433\u2013443 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR65","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbapap.2014.07.012","volume":"1844","author":"JR Marchand","year":"2014","unstructured":"Marchand, J. R. et al. Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy. Biochim. Biophys. Acta 1844, 1765\u20131772 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"2954_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03234-8","volume":"9","author":"MF Langelier","year":"2018","unstructured":"Langelier, M. F., Zandarashvili, L., Aguiar, P. M., Black, B. E. & Pascal, J. M. NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains. Nat. Commun. 9, 844 (2018).","journal-title":"Nat. Commun."},{"key":"2954_CR67","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","volume":"14","author":"R Plummer","year":"2008","unstructured":"Plummer, R. et al. Phase I study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917\u20137923 (2008).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR69","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852\u2013861 (2014).","journal-title":"Lancet Oncol."},{"key":"2954_CR70","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR71","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore, K. N. et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 636\u2013648 (2019).","journal-title":"Lancet Oncol."},{"key":"2954_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR73","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753\u2013763 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson, M. E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558\u2013566 (2019).","journal-title":"Ann. Oncol."},{"key":"2954_CR75","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton, J. K. et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol. 31, 1526\u20131535 (2020).","journal-title":"Ann. Oncol."},{"key":"2954_CR76","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75\u201387 (2017).","journal-title":"Lancet Oncol."},{"key":"2954_CR77","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"2954_CR78","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","volume":"21","author":"JA Ledermann","year":"2020","unstructured":"Ledermann, J. A. et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 710\u2013722 (2020).","journal-title":"Lancet Oncol."},{"key":"2954_CR79","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","volume":"23","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit, R. et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 23, 465\u2013478 (2022).","journal-title":"Lancet Oncol."},{"key":"2954_CR80","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","volume":"19","author":"AM Oza","year":"2018","unstructured":"Oza, A. M. et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 19, 1117\u20131125 (2018).","journal-title":"Lancet Oncol."},{"key":"2954_CR81","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo, J. M. et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J. Clin. Oncol. 37, 2968\u20132973 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR82","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza, M. R. et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial. Gynecol. Oncol. 159, 442\u2013448 (2020).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR83","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","volume":"22","author":"M Friedlander","year":"2021","unstructured":"Friedlander, M. et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 22, 632\u2013642 (2021).","journal-title":"Lancet Oncol."},{"key":"2954_CR84","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P Disilvestro","year":"2023","unstructured":"Disilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR85","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","volume":"174","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2022","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial. Eur. J. Cancer 174, 221\u2013231 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2954_CR86","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 34, 681\u2013692 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR87","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR88","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. 35, 981\u2013992 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR89","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman, R. L. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 381, 2403\u20132415 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115587","volume":"225","author":"RL Coleman","year":"2025","unstructured":"Coleman, R. L. et al. Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: final overall survival and disease-related symptoms results. Eur. J. Cancer 225, 115587 (2025).","journal-title":"Eur. J. Cancer"},{"key":"2954_CR91","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1038\/d41586-021-03714-w","volume":"600","author":"S Makin","year":"2021","unstructured":"Makin, S. What\u2019s next for PARP inhibitors? Nature 600, S36\u2013S38 (2021).","journal-title":"Nature"},{"key":"2954_CR92","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","volume":"20","author":"MR Mirza","year":"2019","unstructured":"Mirza, M. R. et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 20, 1409\u20131419 (2019).","journal-title":"Lancet Oncol."},{"key":"2954_CR93","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"2954_CR94","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620\u2013631 (2021).","journal-title":"Lancet Oncol."},{"key":"2954_CR95","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1200\/JCO.2023.41.16_suppl.5578","volume":"41","author":"G MacAulay Vacheresse","year":"2023","unstructured":"MacAulay Vacheresse, G., Sabri, E., Domingo, S. & Le, T. Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer. J. Clin. Oncol. 41, 5578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR96","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine, E. et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann. Oncol. 34, 1152\u20131164 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR97","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR98","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin, S. N. et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J. Clin. Oncol. 42, 283\u2013299 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR99","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"H Maha","year":"2020","unstructured":"Maha, H. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345\u20132357 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR100","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida, W. et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38, 3763\u20133772 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR101","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR102","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke, N. W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 1, EVIDoa2200043 (2022).","journal-title":"NEJM Evid."},{"key":"2954_CR103","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.23.01868","volume":"42","author":"J Fallah","year":"2023","unstructured":"Fallah, J. et al. FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer. J. Clin. Oncol. 42, 605\u2013613 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR104","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann. Oncol. 34, 772\u2013782 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR105","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","volume":"8","author":"KN Chi","year":"2025","unstructured":"Chi, K. N. et al. Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial. Eur. Urol. Oncol. 8, 986\u2013998 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"2954_CR106","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291\u2013303 (2023).","journal-title":"Lancet"},{"key":"2954_CR107","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","volume":"406","author":"K Fizazi","year":"2025","unstructured":"Fizazi, K. et al. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 406, 461\u2013474 (2025).","journal-title":"Lancet"},{"key":"2954_CR108","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"G Talia","year":"2019","unstructured":"Talia, G. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR109","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler, H. L. et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J. Clin. Oncol. 40, 3929\u20133939 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR110","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","volume":"31","author":"AG Waks","year":"2020","unstructured":"Waks, A. G. et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer. Ann. Oncol. 31, 590\u2013598 (2020).","journal-title":"Ann. Oncol."},{"key":"2954_CR111","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist, B. et al. Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008\u20133015 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR112","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal, H. P. et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann. Oncol. 32, 240\u2013249 (2021).","journal-title":"Ann. Oncol."},{"key":"2954_CR113","doi-asserted-by":"publisher","first-page":"RF5-03","DOI":"10.1158\/1557-3265.SABCS25-RF5-03","volume":"32","author":"N Tung","year":"2026","unstructured":"Tung, N. et al. Abstract RF5-03: OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer. Clin. Cancer Res. 32, RF5-03\u2013RF5-03 (2026).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR114","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham, J. E. et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature 629, 1142\u20131148 (2024).","journal-title":"Nature"},{"key":"2954_CR115","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","volume":"72","author":"FA Dungey","year":"2008","unstructured":"Dungey, F. A., L\u00f6ser, D. A. & Chalmers, A. J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72, 1188\u20131197 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2954_CR116","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ygyno.2018.07.002","volume":"150","author":"Y Bi","year":"2018","unstructured":"Bi, Y. et al. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. Gynecol. Oncol. 150, 534\u2013544 (2018).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR117","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","volume":"23","author":"HW Sim","year":"2021","unstructured":"Sim, H. W. et al. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro. Oncol. 23, 1736\u20131749 (2021).","journal-title":"Neuro. Oncol."},{"key":"2954_CR118","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.20892\/j.issn.2095-3941.2021.0178","volume":"19","author":"Y Kong","year":"2022","unstructured":"Kong, Y. et al. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair. Cancer Biol. Med. 19, 1150\u20131171 (2022).","journal-title":"Cancer Biol. Med."},{"key":"2954_CR119","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","volume":"40","author":"R Tuli","year":"2019","unstructured":"Tuli, R. et al. A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. eBioMedicine 40, 375\u2013381 (2019).","journal-title":"eBioMedicine"},{"key":"2954_CR120","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","volume":"12","author":"A Li","year":"2019","unstructured":"Li, A. et al. Prospects for combining immune checkpoint blockade with PARP inhibition. J. Hematol. Oncol. 12, 98 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2954_CR121","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8+T-cell recruitment via intratumoral sting pathway activation in brca-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"2954_CR122","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR123","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13045-021-01196-x","volume":"14","author":"F Bizzaro","year":"2021","unstructured":"Bizzaro, F. et al. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. J. Hematol. Oncol. 14, 186 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2954_CR124","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat. Med. 27, 1904\u20131909 (2021).","journal-title":"Nat. Med."},{"key":"2954_CR125","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00210-022-02375-4","volume":"396","author":"G Guney Eskiler","year":"2023","unstructured":"Guney Eskiler, G., Ozman, Z., Haciefendi, A. & Cansaran-Duman, D. Novel combination treatment of CDK 4\/6 inhibitors with PARP inhibitors in triple negative breast cancer cells. Naunyn. Schmiedebergs. Arch. Pharmacol. 396, 1031\u20131041 (2023).","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"2954_CR126","doi-asserted-by":"publisher","first-page":"102231","DOI":"10.1016\/j.tranon.2024.102231","volume":"52","author":"CM Roggero","year":"2025","unstructured":"Roggero, C. M. et al. CDK4\/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer. Transl. Oncol. 52, 102231 (2025).","journal-title":"Transl. Oncol."},{"key":"2954_CR127","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/jpm11050340","volume":"11","author":"FG Klein","year":"2021","unstructured":"Klein, F. G. et al. Combination of talazoparib and palbociclib as a potent treatment strategy in bladder cancer. J. Pers. Med. 11, 340 (2021).","journal-title":"J. Pers. Med."},{"key":"2954_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410427","volume":"12","author":"T Luo","year":"2025","unstructured":"Luo, T. et al. Biomimetic targeted co-delivery system engineered from genomic insights for precision treatment of osteosarcoma. Adv. Sci. 12, e2410427 (2025).","journal-title":"Adv. Sci."},{"key":"2954_CR129","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.21.01511","volume":"40","author":"N Li","year":"2022","unstructured":"Li, N. et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J. Clin. Oncol. 40, 2436\u20132446 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR130","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/cas.13947","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci. 110, 1064\u20131075 (2019).","journal-title":"Cancer Sci."},{"key":"2954_CR131","first-page":"e70042","volume":"76","author":"L Wu","year":"2026","unstructured":"Wu, L. et al. Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. CA Cancer J. Clin. 76, e70042 (2026).","journal-title":"CA Cancer J. Clin."},{"key":"2954_CR132","doi-asserted-by":"publisher","first-page":"S579","DOI":"10.1016\/j.annonc.2024.08.827","volume":"35","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. 766PA phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC). Ann. Oncol. 35, S579\u2013S580 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR133","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/cam4.3575","volume":"10","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer. Cancer Med. 10, 109\u2013118 (2021).","journal-title":"Cancer Med."},{"key":"2954_CR134","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-022-06785-z","volume":"197","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. Breast Cancer Res. Treat. 197, 489\u2013501 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"2954_CR135","doi-asserted-by":"publisher","first-page":"13145","DOI":"10.1002\/cam4.5997","volume":"12","author":"F Ciardiello","year":"2023","unstructured":"Ciardiello, F. et al. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Cancer Med. 12, 13145\u201313154 (2023).","journal-title":"Cancer Med."},{"key":"2954_CR136","doi-asserted-by":"publisher","first-page":"e17555","DOI":"10.1200\/JCO.2024.42.16_suppl.e17555","volume":"42","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: a single-arm, prospective phase II trial. J. Clin. Oncol. 42, e17555\u2013e17555 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR137","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","volume":"22","author":"Y Xiong","year":"2020","unstructured":"Xiong, Y. et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia 22, 431\u2013440 (2020).","journal-title":"Neoplasia"},{"key":"2954_CR138","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.1016\/j.ygyno.2024.07.433","volume":"190","author":"C Lan","year":"2024","unstructured":"Lan, C. et al. Pamiparib in combination with surufatinib among patients with platinum-resistant ovarian cancer who received prior PARP inhibitors: a multicenter, single-arm, phase Ib\/II trial (POST-PARPi Trial). Gynecol. Oncol. 190, S291 (2024).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR139","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110\u2013120 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2954_CR140","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109\u20138115 (2006).","journal-title":"Cancer Res."},{"key":"2954_CR141","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res. 74, 287\u2013297 (2014).","journal-title":"Cancer Res."},{"key":"2954_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/srep04026","volume":"4","author":"JM Cunningham","year":"2014","unstructured":"Cunningham, J. M. et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci. Rep. 4, 4026 (2014).","journal-title":"Sci. Rep."},{"key":"2954_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00339-0","volume":"7","author":"J Setton","year":"2021","unstructured":"Setton, J. et al. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. npj Breast Cancer 7, 135 (2021).","journal-title":"npj Breast Cancer"},{"key":"2954_CR144","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 5, 752\u2013767 (2015).","journal-title":"Cancer Discov."},{"key":"2954_CR145","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","volume":"74","author":"IH Ismail","year":"2014","unstructured":"Ismail, I. H. et al. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 74, 4282\u20134294 (2014).","journal-title":"Cancer Res."},{"key":"2954_CR146","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","volume":"12","author":"R Parrotta","year":"2017","unstructured":"Parrotta, R. et al. A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. J. Thorac. Oncol. 12, 1309\u20131319 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"2954_CR147","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","volume":"7","author":"M Javle","year":"2021","unstructured":"Javle, M. et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncol. 7, 693\u2013699 (2021).","journal-title":"JAMA Oncol."},{"key":"2954_CR148","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","volume":"3","author":"JJ Gruber","year":"2022","unstructured":"Gruber, J. J. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat. Cancer 3, 1181\u20131191 (2022).","journal-title":"Nat. Cancer"},{"key":"2954_CR149","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR150","doi-asserted-by":"publisher","first-page":"9022","DOI":"10.1200\/JCO.2019.37.15_suppl.9022","volume":"37","author":"TK Owonikoko","year":"2019","unstructured":"Owonikoko, T. K. et al. A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). J. Clin. Oncol. 37, 9022 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR151","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR152","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo, J. et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 162\u2013174 (2020).","journal-title":"Lancet Oncol."},{"key":"2954_CR153","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida, W. et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur. Urol. 84, 321\u2013330 (2023).","journal-title":"Eur. Urol."},{"key":"2954_CR154","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","volume":"76","author":"CH Marshall","year":"2019","unstructured":"Marshall, C. H. et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur. Urol. 76, 452\u2013458 (2019).","journal-title":"Eur. Urol."},{"key":"2954_CR155","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7, 984\u2013998 (2017).","journal-title":"Cancer Discov."},{"key":"2954_CR156","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","volume":"167","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley, D. M. et al. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol. Oncol. 167, 404\u2013413 (2022).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR157","doi-asserted-by":"publisher","first-page":"e2400406","DOI":"10.1200\/PO-24-00406","volume":"8","author":"TJ George","year":"2024","unstructured":"George, T. J. et al. Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway-deficient neoplasms. JCO Precis. Oncol. 8, e2400406 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR158","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/oncolo\/oyad216.002","volume":"28","author":"G Ged","year":"2023","unstructured":"Ged, G. et al. ORCHID: a phase II study of olaparib in metastatic renal cell carcinoma patients harboring a BAP1 or other DNA repair gene mutations. Oncologist 28, S1 (2023).","journal-title":"Oncologist"},{"key":"2954_CR159","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/cam4.317","volume":"3","author":"TK Owonikoko","year":"2014","unstructured":"Owonikoko, T. K. et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 3, 1579\u20131594 (2014).","journal-title":"Cancer Med."},{"key":"2954_CR160","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho, C. K. et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728\u20132737 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR161","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 19, 497\u2013509 (2018).","journal-title":"Lancet Oncol."},{"key":"2954_CR162","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 1269\u20131282 (2020).","journal-title":"Lancet Oncol."},{"key":"2954_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113580","volume":"200","author":"V Di\u00e9ras","year":"2024","unstructured":"Di\u00e9ras, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial. Eur. J. Cancer 200, 113580 (2024).","journal-title":"Eur. J. Cancer"},{"key":"2954_CR164","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.20.03318","volume":"39","author":"SS Ramalingam","year":"2021","unstructured":"Ramalingam, S. S. et al. Veliparib in combination with platinum- based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study. J. Clin. Oncol. 39, 3633\u20133644 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR165","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cllc.2022.01.005","volume":"23","author":"R Govindan","year":"2022","unstructured":"Govindan, R. et al. Veliparib plus carboplatin and paclitaxel versus investigator\u2019s choice of standard chemotherapy in patients with advanced non\u2013squamous non\u2013small cell lung cancer. Clin. Lung Cancer 23, 214\u2013225 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"2954_CR166","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","volume":"10","author":"JN Sarkaria","year":"2024","unstructured":"Sarkaria, J. N. et al. Efficacy of adding veliparib to temozolomide for patients with MGMT-methylated glioblastoma: a randomized clinical trial. JAMA Oncol. 10, 1637\u20131644 (2024).","journal-title":"JAMA Oncol."},{"key":"2954_CR167","doi-asserted-by":"publisher","first-page":"S1277","DOI":"10.1016\/j.annonc.2023.10.030","volume":"34","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. LBA36 Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): a randomized, double-blind, placebo-controlled, phase III trial. Ann. Oncol. 34, S1277\u2013S1278 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR168","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1016\/j.annonc.2023.09.1944","volume":"34","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. 765P SABRINA study: a phase II study of senaparib monotherapy for patients (pts) with BRCA1\/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC). Ann. Oncol. 34, S521 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR169","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1200\/JCO.2025.43.16_suppl.4045","volume":"43","author":"WS Lee","year":"2025","unstructured":"Lee, W. S. et al. Efficacy of venadaparib plus irinotecan in homologous recombination deficiency (HRD) gene mutations as 3+ line treatment in patients with metastatic gastric cancer (mGC). J. Clin. Oncol. 43, 4045 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR170","doi-asserted-by":"publisher","first-page":"S480","DOI":"10.1016\/j.annonc.2021.08.553","volume":"32","author":"S-A Im","year":"2021","unstructured":"Im, S.-A. et al. 270P Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer. Ann. Oncol. 32, S480 (2021).","journal-title":"Ann. Oncol."},{"key":"2954_CR171","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15019","volume":"41","author":"KS Lee","year":"2023","unstructured":"Lee, K. S. et al. Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1\/2 inhibitor, venadaparib, in patients with pancreatic cancer. J. Clin. Oncol. 41, e15019 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR172","doi-asserted-by":"publisher","first-page":"41307","DOI":"10.18632\/oncotarget.5846","volume":"6","author":"S McGonigle","year":"2015","unstructured":"McGonigle, S. et al. E7449: a dual inhibitor of PARP1\/2 and tankyrase1\/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget 6, 41307\u201341323 (2015).","journal-title":"Oncotarget"},{"key":"2954_CR173","unstructured":"Allarity Therapeutics, Inc. Allarity Therapeutics\u2019 Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer. Allarity Therapeutics https:\/\/www.allarity.com\/press-release\/allarity-therapeutics-stenoparib-shows-clear-clinical-benefit-and-achieves-significant-milestone-with-early-conclusion-of-phase-2-trial-in-advanced-ovarian-cancer\/ (2024)."},{"key":"2954_CR174","doi-asserted-by":"publisher","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","volume":"67","author":"JW Johannes","year":"2024","unstructured":"Johannes, J. W. et al. Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): a CNS-penetrant, PARP1-selective inhibitor. J. Med. Chem. 67, 21717\u201321728 (2024).","journal-title":"J. Med. Chem."},{"key":"2954_CR175","doi-asserted-by":"publisher","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2022-CT007","volume":"82","author":"TA Yap","year":"2022","unstructured":"Yap, T. A. et al. Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations. Cancer Res. 82, CT007 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR176","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2024.42.4_suppl.123","volume":"42","author":"A Azad","year":"2024","unstructured":"Azad, A. et al. PETRANHA: phase 1\/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer\u2013Interim safety and pharmacokinetic results. J. Clin. Oncol. 42, 123 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR177","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/1538-7445.AM2022-2609","volume":"82","author":"K Jamal","year":"2022","unstructured":"Jamal, K. et al. Abstract 2609: AZD9574 is a novel, brain penetrant PARP-1 selective inhibitor with activity in an orthotopic, intracranial xenograft model with aberrant DNA repair. Cancer Res. 82, 2609 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR178","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1200\/JCO.2020.38.15_suppl.6047","volume":"38","author":"J Gong","year":"2020","unstructured":"Gong, J. et al. Phase I study to assess the safety, tolerability, pharmacokinetics\/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors. J. Clin. Oncol. 38, 6047 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR179","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1158\/1538-7445.AM2023-4496","volume":"83","author":"K-S Oh","year":"2023","unstructured":"Oh, K.-S. et al. Abstract 4496: JPI-547, a dual inhibitor of PARP\/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction. Cancer Res. 83, 4496 (2023).","journal-title":"Cancer Res."},{"key":"2954_CR180","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2021.39.15_suppl.3113","volume":"39","author":"S-A Im","year":"2021","unstructured":"Im, S.-A. et al. A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP\/tankyrase in patients with advanced solid tumors. J. Clin. Oncol. 39, 3113 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR181","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/1440-1681.12757","volume":"44","author":"Y Kim","year":"2017","unstructured":"Kim, Y. et al. Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. Clin. Exp. Pharmacol. Physiol. 44, 671\u2013679 (2017).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2954_CR182","unstructured":"Tasly Pharmaceuticals, Inc. TSL1502. Tasly https:\/\/www.taslyus.com\/pipeline\/tsl1502\/ (2020)."},{"key":"2954_CR183","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/j.annonc.2024.08.341","volume":"35","author":"B Lan","year":"2024","unstructured":"Lan, B. et al. 393PA phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations. Ann. Oncol. 35, S384 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR184","unstructured":"Nerviano Medical Sciences. Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma. Nerviano Med. Sci. https:\/\/www.nervianoms.com\/nerviano-medical-sciences-announces-fda-clearance-of-two-inds-for-its-parp1-selective-non-trapping-inhibitor-nms-293-to-start-clinical-studies-in-small-cell-lung-cancer-and-brca-wild-type-ovarian-car\/ (2025)."},{"key":"2954_CR185","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/JCO.2024.42.4_suppl.154","volume":"42","author":"PJ Wysocki","year":"2024","unstructured":"Wysocki, P. J. et al. Anti-tumor activity of RP12146, a PARP1\/2 inhibitor, in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 42, 154 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR186","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s10637-017-0551-z","volume":"36","author":"DAJ van der Biessen","year":"2018","unstructured":"van der Biessen, D. A. J. et al. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1\/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Invest. New Drugs 36, 828\u2013835 (2018).","journal-title":"Invest. New Drugs"},{"key":"2954_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/srep12670","volume":"5","author":"R Dufour","year":"2015","unstructured":"Dufour, R. et al. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci. Rep. 5, 12670 (2015).","journal-title":"Sci. Rep."},{"key":"2954_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt, S. J. et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9, 1849 (2018).","journal-title":"Nat. Commun."},{"key":"2954_CR189","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","volume":"33","author":"E Gogola","year":"2018","unstructured":"Gogola, E. et al. Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell 33, 1078\u20131093.e12 (2018).","journal-title":"Cancer Cell"},{"key":"2954_CR190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00176","volume":"2","author":"BA Carneiro","year":"2018","unstructured":"Carneiro, B. A. et al. Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2 -associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations. JCO Precis. Oncol. 2, 1\u20138 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR191","doi-asserted-by":"publisher","first-page":"17041","DOI":"10.1073\/pnas.1305170110","volume":"110","author":"N Johnson","year":"2013","unstructured":"Johnson, N. et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc. Natl. Acad. Sci. USA 110, 17041\u201317046 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2954_CR192","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz, C. et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann. Oncol. 29, 1203\u20131210 (2018).","journal-title":"Ann. Oncol."},{"key":"2954_CR193","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-21-0748","volume":"27","author":"SL Puhalla","year":"2021","unstructured":"Puhalla, S. L. et al. Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin\/paclitaxel for gBRCA advanced breast cancer (BROCADE3 Crossover). Clin. Cancer Res. 27, 4983\u20134993 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR194","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nsmb.1831","volume":"17","author":"P Bouwman","year":"2010","unstructured":"Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688\u2013695 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2954_CR195","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer, S. M. et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560, 117\u2013121 (2018).","journal-title":"Nature"},{"key":"2954_CR196","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1016\/j.molcel.2021.09.013","volume":"81","author":"S Tirman","year":"2021","unstructured":"Tirman, S. et al. Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. Mol. Cell 81, 4026\u20134040.e8 (2021).","journal-title":"Mol. Cell"},{"key":"2954_CR197","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ncb3626","volume":"19","author":"B Rondinelli","year":"2017","unstructured":"Rondinelli, B. et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat. Cell Biol. 19, 1371\u20131378 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2954_CR198","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"AR Chaudhuri","year":"2016","unstructured":"Chaudhuri, A. R. et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535, 382\u2013387 (2016).","journal-title":"Nature"},{"key":"2954_CR199","doi-asserted-by":"publisher","first-page":"12855","DOI":"10.1093\/nar\/gkab1184","volume":"49","author":"LM Jackson","year":"2021","unstructured":"Jackson, L. M. et al. Loss of MED12 activates the TGF\u03b2 pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells. Nucleic Acids Res. 49, 12855\u201312869 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2954_CR200","doi-asserted-by":"publisher","first-page":"111716","DOI":"10.1016\/j.celrep.2022.111716","volume":"41","author":"A Schrempf","year":"2022","unstructured":"Schrempf, A. et al. POL\u03b8 processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells. Cell Rep. 41, 111716 (2022).","journal-title":"Cell Rep."},{"key":"2954_CR201","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(21)00024-3","volume":"22","author":"DL Richardson","year":"2021","unstructured":"Richardson, D. L. Should we or should we not? Secondary debulking in ovarian cancer. Lancet Oncol. 22, 412\u2013413 (2021).","journal-title":"Lancet Oncol."},{"key":"2954_CR202","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2954_CR203","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","volume":"69","author":"HH Cheng","year":"2016","unstructured":"Cheng, H. H., Pritchard, C. C., Boyd, T., Nelson, P. S. & Montgomery, B. Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur. Urol. 69, 992\u2013995 (2016).","journal-title":"Eur. Urol."},{"key":"2954_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00044","volume":"2","author":"K Banda","year":"2018","unstructured":"Banda, K., Swisher, E. M., Wu, D., Pritchard, C. C. & Gadi, V. K. Somatic reversion of germline BRCA2 mutation confers resistance to Poly(ADP-ribose) polymerase inhibitor therapy. JCO Precis. Oncol. 2, 1\u20136 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR205","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/cancers14010044","volume":"14","author":"R Prados-Carvajal","year":"2022","unstructured":"Prados-Carvajal, R., Irving, E., Lukashchuk, N. & Forment, J. V. Preventing and overcoming resistance to PARP inhibitors: a focus on the clinical landscape. Cancers 14, 44 (2022).","journal-title":"Cancers"},{"key":"2954_CR206","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1073\/pnas.1314302110","volume":"110","author":"D Etemadmoghadam","year":"2013","unstructured":"Etemadmoghadam, D. et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl. Acad. Sci. USA 110, 19489\u201319494 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2954_CR207","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux, S. et al. EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin. Cancer Res. 26, 4206\u20134215 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR208","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/diagnostics10050279","volume":"10","author":"JW Gorski","year":"2020","unstructured":"Gorski, J. W., Ueland, F. R. & Kolesar, J. M. CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer. Diagnostics 10, 279 (2020).","journal-title":"Diagnostics"},{"key":"2954_CR209","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"2954_CR210","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","volume":"188","author":"JV Forment","year":"2018","unstructured":"Forment, J. V. & O\u2019Connor, M. J. Targeting the replication stress response in cancer. Pharmacol. Ther. 188, 155\u2013167 (2018).","journal-title":"Pharmacol. Ther."},{"key":"2954_CR211","doi-asserted-by":"publisher","first-page":"LB","DOI":"10.1158\/1538-7445.AM2018-LB-265","volume":"78","author":"H Xu","year":"2018","unstructured":"Xu, H. et al. Abstract LB-265: the novel oral Chk1 inhibitor, SRA737, is active in both PARP inhibitor resistant and CCNE1 amplified high grade serous ovarian cancers. Cancer Res. 78, LB\u2013265 (2018).","journal-title":"Cancer Res."},{"key":"2954_CR212","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-21-1656","volume":"27","author":"SN Westin","year":"2021","unstructured":"Westin, S. N. et al. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer. Clin. Cancer Res. 27, 6354\u20136365 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR213","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor\u2013resistant homologous recombination\u2013deficient ovarian cancer. Clin. Cancer Res. 29, 2800\u20132807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR214","doi-asserted-by":"publisher","first-page":"zcab003","DOI":"10.1093\/narcan\/zcab003","volume":"3","author":"SP Chowdhuri","year":"2021","unstructured":"Chowdhuri, S. P. & Das, B. B. Top1-PARP1 association and beyond: From DNA topology to break repair. NAR Cancer 3, zcab003 (2021).","journal-title":"NAR Cancer"},{"key":"2954_CR215","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature14157","volume":"518","author":"PA Mateos-Gomez","year":"2015","unstructured":"Mateos-Gomez, P. A. et al. Mammalian polymerase \u03b8 promotes alternative NHEJ and suppresses recombination. Nature 518, 254\u2013257 (2015).","journal-title":"Nature"},{"key":"2954_CR216","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12836-9","volume":"10","author":"JHL Fok","year":"2019","unstructured":"Fok, J. H. L. et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat. Commun. 10, 5065 (2019).","journal-title":"Nat. Commun."},{"key":"2954_CR217","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature 518, 258\u2013262 (2015).","journal-title":"Nature"},{"key":"2954_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102352","volume":"9","author":"L Nappi","year":"2024","unstructured":"Nappi, L. et al. 21P Polymerase theta inhibition in homologous recombination-deficient prostate cancer. ESMO Open 9, 102352 (2024).","journal-title":"ESMO Open"},{"key":"2954_CR219","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23463-8","volume":"12","author":"D Zatreanu","year":"2021","unstructured":"Zatreanu, D. et al. Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat. Commun. 12, 3636 (2021).","journal-title":"Nat. Commun."},{"key":"2954_CR220","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","volume":"2","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nat. Cancer 2, 598\u2013610 (2021).","journal-title":"Nat. Cancer"},{"key":"2954_CR221","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski, S. A. et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 31, 318\u2013332 (2017).","journal-title":"Genes Dev."},{"key":"2954_CR222","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","volume":"16","author":"M Graeser","year":"2010","unstructured":"Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159\u20136168 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR223","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41416-021-01609-1","volume":"126","author":"F Guffanti","year":"2022","unstructured":"Guffanti, F. et al. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. Br. J. Cancer 126, 120\u2013128 (2022).","journal-title":"Br. J. Cancer"},{"key":"2954_CR224","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1158\/1078-0432.CCR-24-3148","volume":"31","author":"G Villacampa","year":"2025","unstructured":"Villacampa, G. et al. RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: a post hoc analysis of the GeparOLA trial. Clin. Cancer Res. 31, 808\u2013814 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00740-y","volume":"13","author":"A Witz","year":"2025","unstructured":"Witz, A. et al. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. Biomark. Res. 13, 31 (2025).","journal-title":"Biomark. Res."},{"key":"2954_CR226","doi-asserted-by":"publisher","first-page":"e390876","DOI":"10.1200\/EDBK_390876","volume":"43","author":"M Friedlander","year":"2023","unstructured":"Friedlander, M., Lee, Y. C. & Tew, W. P. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am. Soc. Clin. Oncol. Educ. Book 43, e390876 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2954_CR227","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","volume":"17","author":"TA Hopkins","year":"2019","unstructured":"Hopkins, T. A. et al. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol. Cancer Res. 17, 409\u2013419 (2019).","journal-title":"Mol. Cancer Res."},{"key":"2954_CR228","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1038\/sj.emboj.7601301","volume":"25","author":"J Y\u00e9lamos","year":"2006","unstructured":"Y\u00e9lamos, J. et al. PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes. EMBO J. 25, 4350\u20134360 (2006).","journal-title":"EMBO J."},{"key":"2954_CR229","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","volume":"122","author":"J Farre\u015b","year":"2013","unstructured":"Farre\u015b, J. et al. Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-irradiation in mice. Blood 122, 44\u201354 (2013).","journal-title":"Blood"},{"key":"2954_CR230","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0192623315621192","volume":"44","author":"Y Zhong","year":"2016","unstructured":"Zhong, Y. et al. Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index < 1. Toxicol. Pathol. 44, 267\u2013278 (2016).","journal-title":"Toxicol. Pathol."},{"key":"2954_CR231","first-page":"83","volume":"118","author":"K Inoue","year":"2017","unstructured":"Inoue, K. & Fry, E. A. Haploinsufficient tumor suppressor genes. Adv. Med. Biol. 118, 83\u2013122 (2017).","journal-title":"Adv. Med. Biol."},{"key":"2954_CR232","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/1541-7786.MCR-10-0496","volume":"9","author":"P Monti","year":"2011","unstructured":"Monti, P. et al. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol. Cancer Res. 9, 271\u2013279 (2011).","journal-title":"Mol. Cancer Res."},{"key":"2954_CR233","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton, J. et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 11, 1626\u20131635 (2021).","journal-title":"Cancer Discov."},{"key":"2954_CR234","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.trecan.2018.08.003","volume":"4","author":"CJ Ryan","year":"2018","unstructured":"Ryan, C. J., Bajrami, I. & Lord, C. J. Synthetic lethality and cancer \u2013 penetrance as the major barrier. Trends Cancer 4, 671\u2013683 (2018).","journal-title":"Trends Cancer"},{"key":"2954_CR235","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","volume":"22","author":"JH Lee","year":"2021","unstructured":"Lee, J. H. & Paull, T. T. Cellular functions of the protein kinase ATM and their relevance to human disease. Nat. Rev. Mol. Cell Biol. 22, 796\u2013814 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2954_CR236","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616\u2013627 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2954_CR237","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.molcel.2007.11.015","volume":"28","author":"JW Harper","year":"2007","unstructured":"Harper, J. W. & Elledge, S. J. The DNA damage response: ten years after. Mol. Cell 28, 739\u2013745 (2007).","journal-title":"Mol. Cell"},{"key":"2954_CR238","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","volume":"15","author":"S Li","year":"2022","unstructured":"Li, S. et al. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J. Hematol. Oncol. 15, 147 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2954_CR239","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona, E. & Fernandez-Capetillo, O. Targeting ATR in cancer. Nat. Rev. Cancer 18, 586\u2013595 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2954_CR240","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721\u2013727 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2954_CR241","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi, M., Kipps, T. & Kurzrock, R. ATM mutations in cancer: therapeutic implications. Mol. Cancer Ther. 15, 1781\u20131791 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","volume":"39","author":"A Guleria","year":"2016","unstructured":"Guleria, A. & Chandna, S. ATM kinase: much more than a DNA damage responsive protein. DNA Repair 39, 1\u201320 (2016).","journal-title":"DNA Repair"},{"key":"2954_CR243","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/em.22397","volume":"61","author":"MK Mustofa","year":"2020","unstructured":"Mustofa, M. K., Tanoue, Y., Tateishi, C., Vaziri, C. & Tateishi, S. Roles of Chk2\/CHEK2 in guarding against environmentally induced DNA damage and replication-stress. Environ. Mol. Mutagen. 61, 730\u2013735 (2020).","journal-title":"Environ. Mol. Mutagen."},{"key":"2954_CR244","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0960-9822(01)00048-3","volume":"11","author":"KE Gurley","year":"2001","unstructured":"Gurley, K. E. & Kemp, C. J. Synthetic lethality between mutation in Atm and DNA-PKcs during murine embryogenesis. Curr. Biol. 11, 191\u2013194 (2001).","journal-title":"Curr. Biol."},{"key":"2954_CR245","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1073\/pnas.051632098","volume":"98","author":"J Sekiguchi","year":"2001","unstructured":"Sekiguchi, J. et al. Genetic interactions between ATM and the nonhomologous end-joining factors in genomic stability and development. Proc. Natl. Acad. Sci. USA 98, 3243\u20133248 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2954_CR246","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M. et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7, 428\u2013430 (2011).","journal-title":"Nat. Chem. Biol."},{"key":"2954_CR247","doi-asserted-by":"publisher","first-page":"32396","DOI":"10.18632\/oncotarget.6136","volume":"6","author":"FK Middleton","year":"2015","unstructured":"Middleton, F. K. et al. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 6, 32396\u201332409 (2015).","journal-title":"Oncotarget"},{"key":"2954_CR248","doi-asserted-by":"publisher","first-page":"217414","DOI":"10.1016\/j.canlet.2024.217414","volume":"611","author":"G Yamamoto","year":"2025","unstructured":"Yamamoto, G. et al. WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer. Cancer Lett. 611, 217414 (2025).","journal-title":"Cancer Lett."},{"key":"2954_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00702-x","volume":"8","author":"D Voulgarelis","year":"2024","unstructured":"Voulgarelis, D. et al. Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers. npj Precis. Oncol. 8, 266 (2024).","journal-title":"npj Precis. Oncol."},{"key":"2954_CR250","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/1878-0261.12882","volume":"15","author":"X Zhao","year":"2021","unstructured":"Zhao, X. et al. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. Mol. Oncol. 15, 1130\u20131145 (2021).","journal-title":"Mol. Oncol."},{"key":"2954_CR251","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas, E. et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 3, e441 (2012).","journal-title":"Cell Death Dis."},{"key":"2954_CR252","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","volume":"20","author":"U Jo","year":"2021","unstructured":"Jo, U. et al. Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents. Mol. Cancer Ther. 20, 1431\u20131441 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR253","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/ng1129","volume":"33","author":"M O\u2019Driscoll","year":"2003","unstructured":"O\u2019Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & Goodship, J. A. A splicing mutation affecting expression of ataxia\u2013telangiectasia and Rad3\u2013related protein (ATR) results in Seckel syndrome. Nat. Genet. 33, 497\u2013501 (2003).","journal-title":"Nat. Genet."},{"key":"2954_CR254","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1101\/gad.14.4.397","volume":"14","author":"EJ Brown","year":"2000","unstructured":"Brown, E. J. & Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397\u2013402 (2000).","journal-title":"Genes Dev."},{"key":"2954_CR255","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66, 801\u2013817 (2017).","journal-title":"Mol. Cell"},{"key":"2954_CR256","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.sbi.2019.12.010","volume":"61","author":"RM Williams","year":"2020","unstructured":"Williams, R. M., Yates, L. A. & Zhang, X. Structures and regulations of ATM and ATR, master kinases in genome integrity. Curr. Opin. Struct. Biol. 61, 98\u2013105 (2020).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2954_CR257","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1126\/science.1065521","volume":"294","author":"D Cortez","year":"2001","unstructured":"Cortez, D., Guntuku, S., Qin, J. & Elledge, S. J. ATR and ATRIP: Partners in checkpoint signaling. Science 294, 1713\u20131716 (2001).","journal-title":"Science"},{"key":"2954_CR258","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/cr.2017.158","volume":"28","author":"Q Rao","year":"2018","unstructured":"Rao, Q. et al. Cryo-EM structure of human ATR-ATRIP complex. Cell Res. 28, 143\u2013156 (2018).","journal-title":"Cell Res."},{"key":"2954_CR259","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication stress. Nat. Cell Biol. 16, 2\u20139 (2014).","journal-title":"Nat. Cell Biol."},{"key":"2954_CR260","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1126\/science.1083430","volume":"300","author":"L Zou","year":"2003","unstructured":"Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542\u20131548 (2003).","journal-title":"Science"},{"key":"2954_CR261","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2\/M DNA damage checkpoint. Genes Dev. 14, 1448\u20131459 (2000).","journal-title":"Genes Dev."},{"key":"2954_CR262","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1046\/j.1365-2184.2000.00191.x","volume":"33","author":"M Molinari","year":"2000","unstructured":"Molinari, M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33, 261\u2013274 (2000).","journal-title":"Cell Prolif."},{"key":"2954_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0009-7","volume":"3","author":"JJ Bower","year":"2017","unstructured":"Bower, J. J. et al. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. npj Breast Cancer 3, 9 (2017).","journal-title":"npj Breast Cancer"},{"key":"2954_CR264","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/sj.bjc.6604208","volume":"98","author":"N Bucher","year":"2008","unstructured":"Bucher, N. & Britten, C. D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 98, 523\u2013528 (2008).","journal-title":"Br. J. Cancer"},{"key":"2954_CR265","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1126\/science.1257216","volume":"347","author":"RL Flynn","year":"2015","unstructured":"Flynn, R. L. et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347, 273\u2013277 (2015).","journal-title":"Science"},{"key":"2954_CR266","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin. Cancer Res. 23, 3097\u20133108 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR267","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","volume":"16","author":"A Min","year":"2017","unstructured":"Min, A. et al. AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells. Mol. Cancer Ther. 16, 566\u2013577 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR268","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and rad3-related (Atr) inhibitor bay 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2021).","journal-title":"Cancer Discov."},{"key":"2954_CR269","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei, S. et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 80, 2094\u20132100 (2020).","journal-title":"Cancer Res."},{"key":"2954_CR270","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1158\/1538-7445.AM2013-3343","volume":"73","author":"SM Guichard","year":"2013","unstructured":"Guichard, S. M. et al. Abstract 3343: The pre-clinical in vitro and in vivo activity of AZD6738: a potent and selective inhibitor of ATR kinase. Cancer Res. 73, 3343 (2013).","journal-title":"Cancer Res."},{"key":"2954_CR271","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah, P. D. et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol. Oncol. 163, 246\u2013253 (2021).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR272","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1200\/JCO.2024.42.16_suppl.5510","volume":"42","author":"F Simpkins","year":"2024","unstructured":"Simpkins, F. et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). J. Clin. Oncol. 42, 5510 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR273","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1200\/PO.20.00439","volume":"5","author":"H Mahdi","year":"2021","unstructured":"Mahdi, H. et al. Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (olaparib combinations). JCO Precis. Oncol. 5, 1432\u20131442 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR274","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring, A. et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasmaMATCH trial (CRUK\/15\/010). Clin. Cancer Res. 29, 4751\u20134759 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR275","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.annonc.2022.03.180","volume":"33","author":"A Tutt","year":"2022","unstructured":"Tutt, A. et al. 161O VIOLETTE: randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann. Oncol. 33, S194\u2013S195 (2022).","journal-title":"Ann. Oncol."},{"key":"2954_CR276","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cncr.35059","volume":"130","author":"S Park","year":"2024","unstructured":"Park, S. et al. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer 130, 541\u2013552 (2024).","journal-title":"Cancer"},{"key":"2954_CR277","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann. Oncol. 33, 193\u2013203 (2022).","journal-title":"Ann. Oncol."},{"key":"2954_CR278","doi-asserted-by":"publisher","first-page":"e005041","DOI":"10.1136\/jitc-2022-005041","volume":"10","author":"M Kwon","year":"2022","unstructured":"Kwon, M. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J. Immunother. Cancer 10, e005041 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2954_CR279","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716\u2013729 (2024).","journal-title":"Nat. Med."},{"key":"2954_CR280","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4618","volume":"10","author":"H Taniguchi","year":"2024","unstructured":"Taniguchi, H. et al. ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Sci. Adv. 10, eado4618 (2024).","journal-title":"Sci. Adv."},{"key":"2954_CR281","doi-asserted-by":"publisher","first-page":"CT222","DOI":"10.1158\/1538-7445.AM2024-CT222","volume":"84","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal, R. et al. Abstract CT222: Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 84, CT222 (2024).","journal-title":"Cancer Res."},{"key":"2954_CR282","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2025.43.16_suppl.5542","volume":"43","author":"RL Roux","year":"2025","unstructured":"Roux, R. L. et al. Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx). J. Clin. Oncol. 43, 5542 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR283","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-21-4335","volume":"82","author":"PC O\u2019Leary","year":"2022","unstructured":"O\u2019Leary, P. C. et al. Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2. Cancer Res. 82, 3950\u20133961 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR284","doi-asserted-by":"publisher","first-page":"1400699","DOI":"10.3389\/fphar.2024.1400699","volume":"15","author":"X-Y Chen","year":"2024","unstructured":"Chen, X.-Y. et al. Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells. Front. Pharmacol. 15, 1400699 (2024).","journal-title":"Front. Pharmacol."},{"key":"2954_CR285","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.2147\/CMAR.S217375","volume":"11","author":"F Ni","year":"2019","unstructured":"Ni, F. et al. Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system. Cancer Manag. Res. 11, 8391\u20138405 (2019).","journal-title":"Cancer Manag. Res."},{"key":"2954_CR286","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1021\/jm101488z","volume":"54","author":"JD Charrier","year":"2011","unstructured":"Charrier, J. D. et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 54, 2320\u20132330 (2011).","journal-title":"J. Med. Chem."},{"key":"2954_CR287","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas, A. et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J. Clin. Oncol. 36, 1594\u20131602 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR288","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","volume":"9","author":"N Takahashi","year":"2023","unstructured":"Takahashi, N. et al. Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial. JAMA Oncol. 9, 1669\u20131677 (2023).","journal-title":"JAMA Oncol."},{"key":"2954_CR289","doi-asserted-by":"publisher","first-page":"CT268","DOI":"10.1158\/1538-7445.AM2023-CT268","volume":"83","author":"ML Abel","year":"2023","unstructured":"Abel, M. L. et al. Abstract CT268: targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial. Cancer Res. 83, CT268 (2023).","journal-title":"Cancer Res."},{"key":"2954_CR290","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41416-023-02542-1","volume":"130","author":"SR Javed","year":"2024","unstructured":"Javed, S. R. et al. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. Br. J. Cancer 130, 467\u2013475 (2024).","journal-title":"Br. J. Cancer"},{"key":"2954_CR291","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton, M. R. et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours. Br. J. Cancer 125, 510\u2013519 (2021).","journal-title":"Br. J. Cancer"},{"key":"2954_CR292","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2021.39.15_suppl.4507","volume":"39","author":"SK Pal","year":"2021","unstructured":"Pal, S. K. et al. A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma. J. Clin. Oncol. 39, 4507 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR293","doi-asserted-by":"publisher","first-page":"e2300635","DOI":"10.1200\/PO.23.00635","volume":"8","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos, P. A. et al. Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses. JCO Precis. Oncol. 8, e2300635 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR294","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1200\/JCO.2023.41.16_suppl.4044","volume":"41","author":"S Stockton","year":"2023","unstructured":"Stockton, S. et al. A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer. J. Clin. Oncol. 41, 4044 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR295","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2021.39.15_suppl.5034","volume":"39","author":"AD Choudhury","year":"2021","unstructured":"Choudhury, A. D. et al. A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 39, 5034 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR296","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1158\/1538-7445.AM2022-2588","volume":"82","author":"A Zimmermann","year":"2022","unstructured":"Zimmermann, A. et al. Abstract 2588: M1774, a novel potent and selective ATR inhibitor, shows antitumor effects as monotherapy and in combination. Cancer Res. 82, 2588 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR297","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.1158\/1538-7445.AM2023-6210","volume":"83","author":"J Hao","year":"2023","unstructured":"Hao, J. et al. Abstract 6210: combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models. Cancer Res. 83, 6210 (2023).","journal-title":"Cancer Res."},{"key":"2954_CR298","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap, T. A. et al. First-in-human study of the ataxia telangiectasia and Rad3-Related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin. Cancer Res. 30, 2057\u20132067 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR299","doi-asserted-by":"publisher","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","volume":"63","author":"U L\u00fccking","year":"2020","unstructured":"L\u00fccking, U. et al. Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models. J. Med. Chem. 63, 7293\u20137325 (2020).","journal-title":"J. Med. Chem."},{"key":"2954_CR300","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner, A. M. et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models. Mol. Cancer Ther. 19, 26\u201338 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15131","volume":"41","author":"MV Ortiz","year":"2023","unstructured":"Ortiz, M. V. et al. A phase 1\/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112. J. Clin. Oncol. 41, e15131 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR302","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1200\/JCO.2024.42.16_suppl.3077","volume":"42","author":"TR Heumann","year":"2024","unstructured":"Heumann, T. R. et al. A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation. J. Clin. Oncol. 42, 3077 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR303","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-024-04745-6","volume":"95","author":"A Krishnamurthy","year":"2025","unstructured":"Krishnamurthy, A. et al. Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemother. Pharmacol. 95, 27 (2025).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2954_CR304","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","volume":"21","author":"A Roulston","year":"2022","unstructured":"Roulston, A. et al. RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol. Cancer Ther. 21, 245\u2013256 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR305","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat. Med. 29, 1400\u20131411 (2023).","journal-title":"Nat. Med."},{"key":"2954_CR306","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01025-1","volume":"9","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi, N. Y. L. et al. Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma. npj Precis. Oncol. 9, 227 (2025).","journal-title":"npj Precis. Oncol."},{"key":"2954_CR307","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","volume":"22","author":"A Turchick","year":"2023","unstructured":"Turchick, A. et al. Selective inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR inhibitors. Mol. Cancer Ther. 22, 859\u2013872 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR308","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/1538-7445.AM2019-369","volume":"79","author":"FT Zenke","year":"2019","unstructured":"Zenke, F. T. et al. Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Cancer Res. 79, 369 (2019).","journal-title":"Cancer Res."},{"key":"2954_CR309","doi-asserted-by":"publisher","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","volume":"210","author":"L Gorecki","year":"2020","unstructured":"Gorecki, L., Andrs, M., Rezacova, M. & Korabecny, J. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy. Pharmacol. Ther. 210, 107518 (2020).","journal-title":"Pharmacol. Ther."},{"key":"2954_CR310","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","volume":"130","author":"HA Burris","year":"2024","unstructured":"Burris, H. A. et al. A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours. Br. J. Cancer 130, 1131\u20131140 (2024).","journal-title":"Br. J. Cancer"},{"key":"2954_CR311","doi-asserted-by":"publisher","first-page":"CT267","DOI":"10.1158\/1538-7445.AM2025-CT267","volume":"85","author":"S Ulahannan","year":"2025","unstructured":"Ulahannan, S. et al. Abstract CT267: first results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors. Cancer Res. 85, CT267 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR312","unstructured":"Artios Pharma. Artios Receives U.S. FDA Fast Track Designation for Alnodesertib in ATM-Negative Metastatic Colorectal Cancer (MCRC). Artios https:\/\/www.artios.com\/press-release\/artios-receives-u-s-fda-fast-track-designation-for-alnodesertib-in-atm-negative-metastatic-colorectal-cancer-mcrc\/ (2025)."},{"key":"2954_CR313","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15642","volume":"38","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Preclinical evaluation of SC0245, a small molecule inhibitor of ATR kinase. J. Clin. Oncol. 38, e15642 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR314","doi-asserted-by":"publisher","first-page":"8102","DOI":"10.1200\/JCO.2024.42.16_suppl.8102","volume":"42","author":"Y Yu","year":"2024","unstructured":"Yu, Y. et al. An open-label, multicenter, phase Ib\/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC). J. Clin. Oncol. 42, 8102 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR315","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrm805","volume":"3","author":"D D\u2019Amours","year":"2002","unstructured":"D\u2019Amours, D. & Jackson, S. P. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat. Rev. Mol. Cell Biol. 3, 317\u2013327 (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2954_CR316","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003277","volume":"9","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair. PLoS Genet. 9, e1003277 (2013).","journal-title":"PLoS Genet."},{"key":"2954_CR317","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1140321","volume":"316","author":"S Matsuoka","year":"2007","unstructured":"Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160\u20131166 (2007).","journal-title":"Science"},{"key":"2954_CR318","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","volume":"14","author":"Y Shiloh","year":"2013","unstructured":"Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197\u2013210 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2954_CR319","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0543-7","volume":"11","author":"C Rothblum-Oviatt","year":"2016","unstructured":"Rothblum-Oviatt, C. et al. Ataxia telangiectasia: a review. Orphanet J. Rare Dis. 11, 159 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"2954_CR320","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jdcr.2022.02.032","volume":"23","author":"MM Sarver","year":"2022","unstructured":"Sarver, M. M., Breglio, K. F. & Olsen, E. A. Ataxia-telangiectasia mutated (ATM) gene mutation in a patient with primary cutaneous marginal zone lymphoma. JAAD Case Rep. 23, 73\u201375 (2022).","journal-title":"JAAD Case Rep."},{"key":"2954_CR321","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V99.1.238","volume":"99","author":"E Camacho","year":"2002","unstructured":"Camacho, E. et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 99, 238\u2013244 (2002).","journal-title":"Blood"},{"key":"2954_CR322","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0686-8","volume":"16","author":"V Mlakar","year":"2017","unstructured":"Mlakar, V. et al. 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol. Cancer 16, 114 (2017).","journal-title":"Mol. Cancer"},{"key":"2954_CR323","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3324\/haematol.2011.048827","volume":"97","author":"A Skowronska","year":"2012","unstructured":"Skowronska, A. et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica 97, 142\u2013146 (2012).","journal-title":"Haematologica"},{"key":"2954_CR324","first-page":"3003","volume":"18","author":"N Begam","year":"2017","unstructured":"Begam, N., Jamil, K. & Raju, S. G. Promoter hypermethylation of the ATM gene as a novel biomarker for breast cancer. Asian Pac. J. Cancer Prev. 18, 3003\u20133009 (2017).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2954_CR325","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski, C. et al. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75, 1131\u20131135 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"2954_CR326","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature17157","volume":"531","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature 531, 471\u2013475 (2016).","journal-title":"Nature"},{"key":"2954_CR327","doi-asserted-by":"publisher","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","volume":"64","author":"I Hickson","year":"2004","unstructured":"Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152\u20139159 (2004).","journal-title":"Cancer Res."},{"key":"2954_CR328","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"ST Durant","year":"2018","unstructured":"Durant, S. T. et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci. Adv. 4, eaat1719 (2018).","journal-title":"Sci. Adv."},{"key":"2954_CR329","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","volume":"19","author":"LC Riches","year":"2020","unstructured":"Riches, L. C. et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically. Mol. Cancer Ther. 19, 13\u201325 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR330","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139333","volume":"131","author":"M Hu","year":"2021","unstructured":"Hu, M. et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J. Clin. Invest. 131, e139333 (2021).","journal-title":"J. Clin. Invest."},{"key":"2954_CR331","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.4161\/cc.29212","volume":"13","author":"E Kubota","year":"2014","unstructured":"Kubota, E. et al. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 13, 2129\u20132137 (2014).","journal-title":"Cell Cycle"},{"key":"2954_CR332","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-022-02384-w","volume":"41","author":"KS Oh","year":"2022","unstructured":"Oh, K. S. et al. A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene 41, 3939\u20133952 (2022).","journal-title":"Oncogene"},{"key":"2954_CR333","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"KG Pike","year":"2018","unstructured":"Pike, K. G. et al. The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). J. Med. Chem. 61, 3823\u20133841 (2018).","journal-title":"J. Med. Chem."},{"key":"2954_CR334","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","volume":"23","author":"A Jucaite","year":"2021","unstructured":"Jucaite, A. et al. Brain exposure of the ATM inhibitor AZD1390 in humans - A positron emission tomography study. Neuro. Oncol. 23, 687\u2013696 (2021).","journal-title":"Neuro. Oncol."},{"key":"2954_CR335","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","volume":"120","author":"JT Yang","year":"2024","unstructured":"Yang, J. T. et al. Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 120, S119\u2013S120 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2954_CR336","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1158\/1538-7445.AM2022-3305","volume":"82","author":"AM Tuma","year":"2022","unstructured":"Tuma, A. M. et al. Abstract 3305: WSD-0628, a novel brain penetrant ATM inhibitor, radiosensitizes GBM and melanoma patient derived xenografts. Cancer Res. 82, 3305 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR337","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1158\/1538-7445.AM2019-3500","volume":"79","author":"T Fuchss","year":"2019","unstructured":"Fuchss, T. et al. Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies. Cancer Res. 79, 3500 (2019).","journal-title":"Cancer Res."},{"key":"2954_CR338","doi-asserted-by":"publisher","first-page":"CT171","DOI":"10.1158\/1538-7445.AM2023-CT171","volume":"83","author":"LL Siu","year":"2023","unstructured":"Siu, L. L. et al. Abstract CT171: A first-in-human phase I study of the ATM inhibitor M4076 in patients with advanced solid tumors (DDRiver Solid Tumors 410): part 1A results. Cancer Res. 83, CT171 (2023).","journal-title":"Cancer Res."},{"key":"2954_CR339","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10637-022-01216-8","volume":"40","author":"SN Waqar","year":"2022","unstructured":"Waqar, S. N. et al. Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. Invest. N. Drugs 40, 596\u2013605 (2022).","journal-title":"Invest. N. Drugs"},{"key":"2954_CR340","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1535-7163.MCT-23-0890","volume":"23","author":"TM Gilmer","year":"2024","unstructured":"Gilmer, T. M. et al. A novel dual ATM\/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors. Mol. Cancer Ther. 23, 751\u2013765 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR341","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexmp.2004.02.001","volume":"77","author":"\u00c5 Holgersson","year":"2004","unstructured":"Holgersson, \u00c5, Nilsson, A., Lewensohn, R. & Kanter, L. Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies. Exp. Mol. Pathol. 77, 1\u20136 (2004).","journal-title":"Exp. Mol. Pathol."},{"key":"2954_CR342","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.chembiol.2015.05.014","volume":"22","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Non-canonical bromodomain within DNA-PKcs promotes DNA damage response and radioresistance through recognizing an IR-induced acetyl-lysine on H2AX. Chem. Biol. 22, 849\u2013861 (2015).","journal-title":"Chem. Biol."},{"key":"2954_CR343","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1182\/blood-2004-07-2888","volume":"105","author":"L Deriano","year":"2005","unstructured":"Deriano, L. et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105, 4776\u20134783 (2005).","journal-title":"Blood"},{"key":"2954_CR344","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1158\/1078-0432.CCR-07-5158","volume":"14","author":"E Willmore","year":"2008","unstructured":"Willmore, E. et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14, 3984\u20133992 (2008).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR345","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1172\/JCI127483","volume":"130","author":"CE Willoughby","year":"2020","unstructured":"Willoughby, C. E. et al. Selective DNA-pkcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. J. Clin. Invest. 130, 258\u2013271 (2020).","journal-title":"J. Clin. Invest."},{"key":"2954_CR346","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-23-1531","volume":"30","author":"A Laroche-Clary","year":"2024","unstructured":"Laroche-Clary, A. et al. Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. Clin. Cancer Res. 30, 629\u2013637 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR347","doi-asserted-by":"publisher","first-page":"20445","DOI":"10.18632\/aging.103847","volume":"12","author":"B Zheng","year":"2020","unstructured":"Zheng, B. et al. Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth. Aging 12, 20445\u201320456 (2020).","journal-title":"Aging"},{"key":"2954_CR348","doi-asserted-by":"publisher","first-page":"10463","DOI":"10.2147\/CMAR.S208720","volume":"11","author":"P Munster","year":"2019","unstructured":"Munster, P. et al. First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy. Cancer Manag. Res. 11, 10463\u201310476 (2019).","journal-title":"Cancer Manag. Res."},{"key":"2954_CR349","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41416-023-02487-5","volume":"130","author":"JL Zhao","year":"2024","unstructured":"Zhao, J. L. et al. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1\/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). Br. J. Cancer 130, 53\u201362 (2024).","journal-title":"Br. J. Cancer"},{"key":"2954_CR350","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1200\/JCO.23.00493","volume":"41","author":"R Rahman","year":"2023","unstructured":"Rahman, R. et al. Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using bayesian adaptive randomization. J. Clin. Oncol. 41, 5524\u20135535 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR351","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","volume":"19","author":"FT Zenke","year":"2020","unstructured":"Zenke, F. T. et al. Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models. Mol. Cancer Ther. 19, 1091\u20131101 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR352","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41416-020-01151-6","volume":"124","author":"MTJ van Bussel","year":"2021","unstructured":"van Bussel, M. T. J. et al. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. Br. J. Cancer 124, 728\u2013735 (2021).","journal-title":"Br. J. Cancer"},{"key":"2954_CR353","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","volume":"118","author":"M Samuels","year":"2024","unstructured":"Samuels, M. et al. A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 118, 743\u2013756 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2954_CR354","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102217","volume":"9","author":"B Perez","year":"2024","unstructured":"Perez, B. et al. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open 9, 102217 (2024).","journal-title":"ESMO Open"},{"key":"2954_CR355","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","volume":"30","author":"PB Romesser","year":"2024","unstructured":"Romesser, P. B. et al. A phase Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer. Clin. Cancer Res. 30, 695\u2013702 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR356","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1111\/cts.13657","volume":"16","author":"A Becker","year":"2023","unstructured":"Becker, A. et al. Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: effect of food and pharmacokinetics of an oral suspension. Clin. Transl. Sci. 16, 2628\u20132639 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"2954_CR357","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1200\/JCO.2024.42.16_suppl.2076","volume":"42","author":"N Majd","year":"2024","unstructured":"Majd, N. et al. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. J. Clin. Oncol. 42, 2076 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR358","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1200\/JCO.2025.43.16_suppl.5069","volume":"43","author":"HA Gay","year":"2025","unstructured":"Gay, H. A. et al. A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): phase l results. J. Clin. Oncol. 43, 5069 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR359","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1021\/acs.jmedchem.9b01684","volume":"63","author":"FW Goldberg","year":"2020","unstructured":"Goldberg, F. W. et al. The discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- a]pyridin-6-yl)amino]-9-(tetrahydro-2 H-pyran-4-yl)-7,9-dihydro-8 H-purin-8-one (AZD7648), a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor. J. Med. Chem. 63, 3461\u20133471 (2020).","journal-title":"J. Med. Chem."},{"key":"2954_CR360","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1535-7163.MCT-21-0420","volume":"21","author":"A Anastasia","year":"2022","unstructured":"Anastasia, A. et al. The DNA-PK inhibitor AZD7648 sensitizes patient-derived ovarian cancer xenografts to pegylated liposomal doxorubicin and olaparib preventing abdominal metastases. Mol. Cancer Ther. 21, 555\u2013567 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR361","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41416-025-03053-x","volume":"133","author":"TA Yap","year":"2025","unstructured":"Yap, T. A. et al. The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I\/IIa study. Br. J. Cancer 133, 168\u2013177 (2025).","journal-title":"Br. J. Cancer"},{"key":"2954_CR362","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","volume":"17","author":"CR Timme","year":"2018","unstructured":"Timme, C. R., Rath, B. H., O\u2019Neill, J. W., Camphausen, K. & Tofilon, P. J. The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts. Mol. Cancer Ther. 17, 1207\u20131216 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR363","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/s41388-020-1250-3","volume":"39","author":"MKND Hutchinson","year":"2020","unstructured":"Hutchinson, M. K. N. D., Mierzwa, M. & D\u2019Silva, N. J. Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer. Oncogene 39, 3638\u20133649 (2020).","journal-title":"Oncogene"},{"key":"2954_CR364","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e15132","volume":"42","author":"J Yu","year":"2024","unstructured":"Yu, J. et al. First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort. J. Clin. Oncol. 42, e15132 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR365","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-15-0996","volume":"15","author":"MC Smith","year":"2016","unstructured":"Smith, M. C. et al. Characterization of LY3023414, a novel PI3K\/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth. Mol. Cancer Ther. 15, 2344\u20132356 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR366","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-17-3421","volume":"24","author":"JC Bendell","year":"2018","unstructured":"Bendell, J. C. et al. A first-in-human phase 1 study of LY3023414, an Oral PI3K\/mTOR dual inhibitor, in patients with advanced cancer. Clin. Cancer Res. 24, 3253\u20133262 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR367","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1007\/s10637-020-00968-5","volume":"38","author":"S Kondo","year":"2020","unstructured":"Kondo, S. et al. Phase 1 dose-escalation study of a novel oral PI3K\/mTOR dual inhibitor, LY3023414, in patients with cancer. Invest. New Drugs 38, 1836\u20131845 (2020).","journal-title":"Invest. New Drugs"},{"key":"2954_CR368","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-21-2326","volume":"28","author":"CJ Sweeney","year":"2022","unstructured":"Sweeney, C. J. et al. Phase Ib\/II study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 28, 2237\u20132247 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR369","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/cncr.32677","volume":"126","author":"MM Rubinstein","year":"2020","unstructured":"Rubinstein, M. M. et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer 126, 1274\u20131282 (2020).","journal-title":"Cancer"},{"key":"2954_CR370","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1158\/1078-0432.CCR-20-3242","volume":"27","author":"DS Hong","year":"2021","unstructured":"Hong, D. S. et al. Preclinical evaluation and phase ib study of prexasertib, a chk1 inhibitor, and samotolisib (LY3023414), a dual PI3K\/mTOR inhibitor. Clin. Cancer Res. 27, 1864\u20131874 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR371","doi-asserted-by":"publisher","first-page":"20353","DOI":"10.1002\/cam4.6621","volume":"12","author":"EG Chiorean","year":"2023","unstructured":"Chiorean, E. G. et al. Efficacy and safety of abemaciclib alone and with PI3K\/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: a randomized controlled trial. Cancer Med. 12, 20353\u201320364 (2023).","journal-title":"Cancer Med."},{"key":"2954_CR372","doi-asserted-by":"publisher","first-page":"V487","DOI":"10.1093\/annonc\/mdx380.064","volume":"28","author":"P Garrido Lopez","year":"2017","unstructured":"Garrido Lopez, P. et al. Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC. Ann. Oncol. 28, V487 (2017).","journal-title":"Ann. Oncol."},{"key":"2954_CR373","doi-asserted-by":"publisher","first-page":"VI441","DOI":"10.1093\/annonc\/mdw383.74","volume":"27","author":"M Johnson","year":"2016","unstructured":"Johnson, M. et al. A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC). Ann. Oncol. 27, VI441 (2016).","journal-title":"Ann. Oncol."},{"key":"2954_CR374","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pbiomolbio.2019.06.003","volume":"147","author":"D Baretic","year":"2019","unstructured":"Baretic, D. et al. Structural insights into the critical DNA damage sensors DNA-PKcs, ATM and ATR. Prog. Biophys. Mol. Biol. 147, 4\u201316 (2019).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"2954_CR375","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00395-017-0657-7","volume":"112","author":"X Rossello","year":"2017","unstructured":"Rossello, X. et al. The role of PI3K\u03b1 isoform in cardioprotection. Basic Res. Cardiol. 112, 66 (2017).","journal-title":"Basic Res. Cardiol."},{"key":"2954_CR376","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pbiomolbio.2020.09.003","volume":"163","author":"M Hammel","year":"2021","unstructured":"Hammel, M. et al. Visualizing functional dynamicity in the DNA-dependent protein kinase holoenzyme DNA-PK complex by integrating SAXS with cryo-EM. Prog. Biophys. Mol. Biol. 163, 74\u201386 (2021).","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"2954_CR377","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/13543776.2021.1866540","volume":"31","author":"S Hu","year":"2021","unstructured":"Hu, S. et al. Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010\u2013present). Expert Opin. Ther. Pat. 31, 435\u2013452 (2021).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2954_CR378","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.bjc.6605201","volume":"101","author":"C Beskow","year":"2009","unstructured":"Beskow, C. et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br. J. Cancer 101, 816\u2013821 (2009).","journal-title":"Br. J. Cancer"},{"key":"2954_CR379","first-page":"912","volume":"39","author":"J Dong","year":"2018","unstructured":"Dong, J. et al. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair. Oncol. Rep. 39, 912\u2013920 (2018).","journal-title":"Oncol. Rep."},{"key":"2954_CR380","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","volume":"3","author":"J Bartek","year":"2003","unstructured":"Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421\u2013429 (2003).","journal-title":"Cancer Cell"},{"key":"2954_CR381","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/ijc.32814","volume":"147","author":"CL Heidler","year":"2020","unstructured":"Heidler, C. L. et al. Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. Int. J. Cancer 147, 1059\u20131070 (2020).","journal-title":"Int. J. Cancer"},{"key":"2954_CR382","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1634\/theoncologist.2020-0491","volume":"25","author":"ME Gatti-Mays","year":"2020","unstructured":"Gatti-Mays, M. E. et al. A phase II single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA wild-type, advanced triple-negative breast cancer. Oncologist 25, 1013\u2013e1824 (2020).","journal-title":"Oncologist"},{"key":"2954_CR383","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cllc.2021.04.005","volume":"22","author":"LA Byers","year":"2021","unstructured":"Byers, L. A. et al. A phase II trial of prexasertib (LY2606368) in patients with extensive-stage small-cell lung cancer. Clin. Lung Cancer 22, 531\u2013540 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"2954_CR384","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","volume":"167","author":"PA Konstantinopoulos","year":"2022","unstructured":"Konstantinopoulos, P. A. et al. A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecol. Oncol. 167, 213\u2013225 (2022).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR385","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2022.40.16_suppl.11503","volume":"40","author":"EK Slotkin","year":"2022","unstructured":"Slotkin, E. K. et al. A phase I\/II study of prexasertib in combination with irinotecan in patients with relapsed\/refractory desmoplastic small round cell tumor and rhabdomyosarcoma. J. Clin. Oncol. 40, 11503 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR386","doi-asserted-by":"publisher","first-page":"S564","DOI":"10.1016\/j.annonc.2024.08.805","volume":"35","author":"J-M Lee","year":"2024","unstructured":"Lee, J.-M. et al. 744PA phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296). Ann. Oncol. 35, S564\u2013S565 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR387","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.18632\/oncotarget.4919","volume":"7","author":"MI Walton","year":"2016","unstructured":"Walton, M. I. et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and E\u03bc-MYC driven B-cell lymphoma. Oncotarget 7, 2329\u20132342 (2016).","journal-title":"Oncotarget"},{"key":"2954_CR388","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1158\/0008-5472.CAN-19-1372","volume":"80","author":"RF Rogers","year":"2020","unstructured":"Rogers, R. F. et al. CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. Cancer Res. 80, 1735\u20131747 (2020).","journal-title":"Cancer Res."},{"key":"2954_CR389","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","volume":"129","author":"R Kristeleit","year":"2023","unstructured":"Kristeleit, R. et al. A Phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. Br. J. Cancer 129, 38\u201345 (2023).","journal-title":"Br. J. Cancer"},{"key":"2954_CR390","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","volume":"29","author":"R Jones","year":"2023","unstructured":"Jones, R. et al. A Phase I\/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clin. Cancer Res. 29, 331\u2013340 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR391","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.1016\/j.annonc.2023.09.1868","volume":"34","author":"A Drilon","year":"2023","unstructured":"Drilon, A. et al. 682P Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA). Ann. Oncol. 34, S477 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR392","doi-asserted-by":"publisher","first-page":"S793","DOI":"10.1016\/j.annonc.2022.07.665","volume":"33","author":"WH Miller","year":"2022","unstructured":"Miller, W. H. et al. 537PA phase I\/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer. Ann. Oncol. 33, S793\u2013S794 (2022).","journal-title":"Ann. Oncol."},{"key":"2954_CR393","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-23-2005","volume":"29","author":"BM Huffman","year":"2023","unstructured":"Huffman, B. M. et al. A phase I expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin. Cancer Res. 29, 5047\u20135056 (2023).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR394","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/1538-7445.AM2017-295","volume":"77","author":"A Vo","year":"2017","unstructured":"Vo, A. et al. Abstract 295: CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition. Cancer Res. 77, 295 (2017).","journal-title":"Cancer Res."},{"key":"2954_CR395","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1158\/1538-7445.AM2025-2903","volume":"85","author":"Y Kumagai","year":"2025","unstructured":"Kumagai, Y. et al. Abstract 2903: evaluation of SMP-3124, a novel liposome-encapsulated CHK1 inhibitor, in patient-derived preclinical models of treatment-resistant ovarian cancer. Cancer Res. 85, 2903 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR396","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.2147\/OTT.S297132","volume":"14","author":"M Li","year":"2021","unstructured":"Li, M. et al. Gdc-0575, a chk1 inhibitor, impairs the development of colitis and colitis-associated cancer by inhibiting ccr2+ macrophage infiltration in mice. Onco. Targets Ther. 14, 2661\u20132672 (2021).","journal-title":"Onco. Targets Ther."},{"key":"2954_CR397","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2020.05.072","volume":"159","author":"SR DeJong","year":"2020","unstructured":"DeJong, S. R. et al. Gemcitabine and novel Chk1 inhibitor GDC-0575 demonstrate synergistic effect against high-grade serous ovarian cancer in 3D cell culture, PDX models and patient tumors. Gynecol. Oncol. 159, 90 (2020).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR398","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/annonc\/mdy076","volume":"29","author":"A Italiano","year":"2018","unstructured":"Italiano, A. et al. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann. Oncol. 29, 1304\u20131311 (2018).","journal-title":"Ann. Oncol."},{"key":"2954_CR399","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10637-014-0114-5","volume":"32","author":"E Calvo","year":"2014","unstructured":"Calvo, E. et al. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Investig. N. Drugs 32, 955\u2013968 (2014).","journal-title":"Investig. N. Drugs"},{"key":"2954_CR400","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2017.03.001","volume":"108","author":"T Wehler","year":"2017","unstructured":"Wehler, T. et al. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer 108, 212\u2013216 (2017).","journal-title":"Lung Cancer"},{"key":"2954_CR401","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","volume":"34","author":"G Scagliotti","year":"2016","unstructured":"Scagliotti, G. et al. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Invest. New Drugs 34, 625\u2013635 (2016).","journal-title":"Invest. New Drugs"},{"key":"2954_CR402","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3131-x","volume":"17","author":"B Laquente","year":"2017","unstructured":"Laquente, B. et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer 17, 137 (2017).","journal-title":"BMC Cancer"},{"key":"2954_CR403","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","volume":"73","author":"E Sausville","year":"2014","unstructured":"Sausville, E. et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73, 539\u2013549 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2954_CR404","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","volume":"61","author":"JA Webster","year":"2017","unstructured":"Webster, J. A. et al. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk. Res. 61, 108\u2013116 (2017).","journal-title":"Leuk. Res."},{"key":"2954_CR405","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1538-7445.AM2021-1461","volume":"81","author":"JH-J Han","year":"2021","unstructured":"Han, J. H.-J. et al. Abstract 1461: PHI-101, a potent and novel inhibitor of CHK2 in ovarian and breast cancer cells. Cancer Res. 81, 1461 (2021).","journal-title":"Cancer Res."},{"key":"2954_CR406","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2954_CR407","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2023-185606","volume":"142","author":"S-S Yoon","year":"2023","unstructured":"Yoon, S.-S. et al. PHI-101 as a potent next-generation FLT3 inhibitor, overcome resistances in previously treated patients with FLT3-ITD or TKD acute myeloid leukemia: results of a phase Ia\/Ib clinical trial. Blood 142, 4283 (2023).","journal-title":"Blood"},{"key":"2954_CR408","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.leukres.2017.11.004","volume":"64","author":"TB Garcia","year":"2018","unstructured":"Garcia, T. B., Fosmire, S. P. & Porter, C. C. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk. Res. 64, 30\u201333 (2018).","journal-title":"Leuk. Res."},{"key":"2954_CR409","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.chembiol.2019.10.013","volume":"27","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Development and characterization of a Wee1 kinase degrader. Cell Chem. Biol. 27, 57\u201365.e9 (2020).","journal-title":"Cell Chem. Biol."},{"key":"2954_CR410","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cellsig.2015.01.020","volume":"27","author":"J Vera","year":"2015","unstructured":"Vera, J. et al. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Cell. Signal. 27, 951\u2013960 (2015).","journal-title":"Cell. Signal."},{"key":"2954_CR411","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/0008-5472.CAN-18-3374","volume":"80","author":"J Liang","year":"2020","unstructured":"Liang, J. et al. Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition. Cancer Res. 80, 510\u2013523 (2020).","journal-title":"Cancer Res."},{"key":"2954_CR412","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00787-4","volume":"9","author":"D Kim","year":"2025","unstructured":"Kim, D. et al. Cyclin E1\/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. npj Precis. Oncol. 9, 3 (2025).","journal-title":"npj Precis. Oncol."},{"key":"2954_CR413","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141\u20131152 (2014).","journal-title":"Cancer Res."},{"key":"2954_CR414","doi-asserted-by":"publisher","first-page":"110448","DOI":"10.1016\/j.celrep.2022.110448","volume":"38","author":"ES Knudsen","year":"2022","unstructured":"Knudsen, E. S. et al. CDK\/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Rep. 38, 110448 (2022).","journal-title":"Cell Rep."},{"key":"2954_CR415","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2019.12.023","volume":"472","author":"A Sand","year":"2020","unstructured":"Sand, A. et al. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer. Cancer Lett. 472, 119\u2013131 (2020).","journal-title":"Cancer Lett."},{"key":"2954_CR416","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. Clin. Cancer Res. 24, 6594\u20136610 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR417","doi-asserted-by":"publisher","first-page":"e57523","DOI":"10.1371\/journal.pone.0057523","volume":"8","author":"JM Kreahling","year":"2013","unstructured":"Kreahling, J. M. et al. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS ONE 8, e57523 (2013).","journal-title":"PLoS ONE"},{"key":"2954_CR418","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen, S. et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 34, 4371\u20134380 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR419","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo, K. C. et al. Dose escalation trial of the WEE1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J. Clin. Oncol. 37, 2643\u20132650 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR420","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","volume":"26","author":"AM Oza","year":"2020","unstructured":"Oza, A. M. et al. A biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin. Cancer Res. 26, 4767\u20134776 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR421","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen, S. et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with tp53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J. Clin. Oncol. 34, 4354\u20134361 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR422","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux, S. et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 281\u2013292 (2021).","journal-title":"Lancet"},{"key":"2954_CR423","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.21.01435","volume":"39","author":"JF Seligmann","year":"2021","unstructured":"Seligmann, J. F. et al. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. J. Clin. Oncol. 39, 3705\u20133715 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR424","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/cncr.33048","volume":"126","author":"S Park","year":"2020","unstructured":"Park, S. et al. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. Cancer 126, 4002\u20134012 (2020).","journal-title":"Cancer"},{"key":"2954_CR425","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1200\/JCO.2024.42.16_suppl.8545","volume":"42","author":"B Pellini","year":"2024","unstructured":"Pellini, B. et al. A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC). J. Clin. Oncol. 42, 8545 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR426","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-24-0013","volume":"30","author":"N Reinmuth","year":"2024","unstructured":"Reinmuth, N. et al. Novel combinations of immunotherapies or DNA damage repair inhibitors in platinum-refractory extensive-stage small cell lung cancer: the phase II BALTIC study. Clin. Cancer Res. 30, 4055\u20134067 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR427","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu, S. et al. Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J. Clin. Oncol. 41, 1725\u20131734 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR428","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.20.03167","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu, J. F. et al. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J. Clin. Oncol. 39, 1531\u20131539 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR429","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ygyno.2023.06.512","volume":"176","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. Gynecol. Oncol. 176, S33\u2013S35 (2023).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR430","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2019.37.15_suppl.5513","volume":"37","author":"KN Moore","year":"2019","unstructured":"Moore, K. N. et al. Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): an open label, four-arm, phase II study. J. Clin. Oncol. 37, 5513 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR431","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","volume":"27","author":"TE Keenan","year":"2021","unstructured":"Keenan, T. E. et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. Clin. Cancer Res. 27, 983\u2013991 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR432","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/PO.20.00372","volume":"5","author":"AP Chen","year":"2021","unstructured":"Chen, A. P. et al. Molecular profiling-based assignment of cancer therapy (NCI-MPACT): a randomized multicenter phase II trial. JCO Precis. Oncol. 5, 133\u2013144 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR433","doi-asserted-by":"publisher","first-page":"CT029","DOI":"10.1158\/1538-7445.AM2021-CT029","volume":"81","author":"KA Cole","year":"2021","unstructured":"Cole, K. A. et al. Abstract CT029: pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children\u2019s Oncology Group Study (ADVL1312). Cancer Res. 81, CT029 (2021).","journal-title":"Cancer Res."},{"key":"2954_CR434","doi-asserted-by":"publisher","first-page":"CT016","DOI":"10.1158\/1538-7445.AM2021-CT016","volume":"81","author":"A Tolcher","year":"2021","unstructured":"Tolcher, A. et al. Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors. Cancer Res. 81, CT016 (2021).","journal-title":"Cancer Res."},{"key":"2954_CR435","doi-asserted-by":"publisher","first-page":"CT029","DOI":"10.1158\/1538-7445.AM2022-CT029","volume":"82","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Abstract CT029: safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Cancer Res. 82, CT029 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR436","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ygyno.2025.03.060","volume":"200","author":"F Simpkins","year":"2025","unstructured":"Simpkins, F. et al. Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: outcomes from part 1b of the DENALI study (GOG-3066). Gynecol. Oncol. 200, 8\u20139 (2025).","journal-title":"Gynecol. Oncol."},{"key":"2954_CR437","unstructured":"Zentalis Pharmaceuticals. Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer. Zentalis https:\/\/ir.zentalis.com\/news-releases\/news-release-details\/zentalis-pharmaceuticals-shares-updated-clinical-data\/ (2025)."},{"key":"2954_CR438","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2023.41.16_suppl.5513","volume":"41","author":"JF Liu","year":"2023","unstructured":"Liu, J. F. et al. Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R\/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). J. Clin. Oncol. 41, 5513 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR439","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.1200\/JCO.2024.42.16_suppl.11525","volume":"42","author":"V Avutu","year":"2024","unstructured":"Avutu, V. et al. Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R\/R) osteosarcoma. J. Clin. Oncol. 42, 11525 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR440","unstructured":"Zentalis Pharmaceuticals. Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies. Zentalis https:\/\/ir.zentalis.com\/news-releases\/news-release-details\/zentalis-pharmaceuticals-announces-azenosertib-fast-track\/ (2025)."},{"key":"2954_CR441","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2023.41.16_suppl.3012","volume":"41","author":"H Gelderblom","year":"2023","unstructured":"Gelderblom, H. et al. Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors\u2014Safety, pharmacokinetic, and preliminary antitumor activity data. J. Clin. Oncol. 41, 3012 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR442","doi-asserted-by":"publisher","first-page":"A023","DOI":"10.1158\/1535-7163.TARG-23-A023","volume":"22","author":"D Gallo","year":"2023","unstructured":"Gallo, D. et al. Abstract A023: preclinical development of PKMYT1 and WEE1 inhibitor combinations. Mol. Cancer Ther. 22, A023 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR443","doi-asserted-by":"publisher","first-page":"CT262","DOI":"10.1158\/1538-7445.AM2025-CT262","volume":"85","author":"A Schram","year":"2025","unstructured":"Schram, A. et al. Abstract CT262: efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656). Cancer Res. 85, CT262 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR444","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1200\/JCO.2025.43.16_suppl.8098","volume":"43","author":"V Gambardella","year":"2025","unstructured":"Gambardella, V. et al. Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): determination of recommended dose (RD) from a phase 1 escalation. J. Clin. Oncol. 43, 8098 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR445","doi-asserted-by":"publisher","first-page":"TPS2702","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2702","volume":"40","author":"KP Papadopoulos","year":"2022","unstructured":"Papadopoulos, K. P. et al. A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors. J. Clin. Oncol. 40, TPS2702 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR446","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1538-7445.AM2023-6185","volume":"83","author":"L Piggott","year":"2023","unstructured":"Piggott, L. et al. Abstract 6185: Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of glioblastoma. Cancer Res. 83, 6185 (2023).","journal-title":"Cancer Res."},{"key":"2954_CR447","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1158\/1538-7445.AM2024-3370","volume":"84","author":"L Piggott","year":"2024","unstructured":"Piggott, L., Imedio, E. R. & Staehli, F. Abstract 3370: anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer. Cancer Res. 84, 3370 (2024).","journal-title":"Cancer Res."},{"key":"2954_CR448","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e15052","volume":"40","author":"C-C Lin","year":"2022","unstructured":"Lin, C.-C. et al. A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 40, e15052 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR449","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/MCB.17.2.571","volume":"17","author":"F Liu","year":"1997","unstructured":"Liu, F., Stanton, J. J., Wu, Z. & Piwnica-Worms, H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and golgi complex. Mol. Cell. Biol. 17, 571\u2013583 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"2954_CR450","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","volume":"604","author":"D Gallo","year":"2022","unstructured":"Gallo, D. et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 604, 749\u2013756 (2022).","journal-title":"Nature"},{"key":"2954_CR451","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0092-8674(91)90266-2","volume":"64","author":"K Lundgren","year":"1991","unstructured":"Lundgren, K. et al. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 64, 1111\u20131122 (1991).","journal-title":"Cell"},{"key":"2954_CR452","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.celrep.2015.11.021","volume":"13","author":"CM Toledo","year":"2015","unstructured":"Toledo, C. M. et al. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep. 13, 2425\u20132439 (2015).","journal-title":"Cell Rep."},{"key":"2954_CR453","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcad029","volume":"5","author":"J Benada","year":"2023","unstructured":"Benada, J. et al. Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma. NAR Cancer 5, zcad029 (2023).","journal-title":"NAR Cancer"},{"key":"2954_CR454","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/0008-5472.CAN-19-1961","volume":"79","author":"CW Lewis","year":"2019","unstructured":"Lewis, C. W. et al. Upregulation of MyT1 promotes acquired resistance of cancer cells to WEE1 inhibition. Cancer Res. 79, 5971\u20135985 (2019).","journal-title":"Cancer Res."},{"key":"2954_CR455","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102346","volume":"9","author":"F Simpkins","year":"2024","unstructured":"Simpkins, F. et al. 15O Targeting CCNE1-amplified ovarian and endometrial cancers by combined inhibition of PKYMT1 and ATR. ESMO Open 9, 102346 (2024).","journal-title":"ESMO Open"},{"key":"2954_CR456","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1016\/j.annonc.2024.05.419","volume":"35","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg, Z. A. et al. 504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study). Ann. Oncol. 35, S201 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR457","doi-asserted-by":"publisher","first-page":"CT262","DOI":"10.1158\/1538-7445.AM2025-CT262","volume":"85","author":"AM Schram","year":"2025","unstructured":"Schram, A. M. et al. Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656). Cancer Res. 85, CT262 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR458","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1538-7445.AM2025-357","volume":"85","author":"L Shi","year":"2025","unstructured":"Shi, L. et al. Abstract 357: Detailed mechanistic understanding of ACR-2316, a novel, clinical-stage WEE1\/PKMYT1 inhibitor, rationally designed for superior single-agent activity through potent activation of CDK1, CDK2, and PLK1 using Acrivon\u2019s machine learning-driven AP3 platform. Cancer Res. 85, 357 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR459","doi-asserted-by":"publisher","first-page":"C112","DOI":"10.1158\/1535-7163.TARG-25-C112","volume":"24","author":"P Lombardo","year":"2025","unstructured":"Lombardo, P. et al. Abstract C112: ACR-2316 is a novel, differentiated, clinical-stage WEE1\/PKMYT1 inhibitor designed by Acrivon\u2019s Generative Phosphoproteomics AP3 Platform for optimal pro-apoptotic pathway effects in tumor cells resulting in superior preclinical activity. Mol. Cancer Ther. 24, C112 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR460","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223084","volume":"14","author":"P Li","year":"2019","unstructured":"Li, P., Zhang, X., Gu, L., Zhou, J. & Deng, D. P16 methylation increases the sensitivity of cancer cells to the CDK4\/6 inhibitor palbociclib. PLoS ONE 14, e0223084 (2019).","journal-title":"PLoS ONE"},{"key":"2954_CR461","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00624-8","volume":"10","author":"R Foy","year":"2024","unstructured":"Foy, R., Lew, K. X. & Saurin, A. T. The search for CDK4\/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays. NPJ Breast Cancer 10, 19 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"2954_CR462","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1158\/1535-7163.MCT-15-0519","volume":"15","author":"NA Jabbour-Leung","year":"2016","unstructured":"Jabbour-Leung, N. A. et al. Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant Triple-negative breast cancer. Mol. Cancer Ther. 15, 593\u2013607 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR463","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-32","volume":"14","author":"J Kang","year":"2014","unstructured":"Kang, J., Sergio, C. M., Sutherland, R. L. & Musgrove, E. A. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4\/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 14, 32 (2014).","journal-title":"BMC Cancer"},{"key":"2954_CR464","doi-asserted-by":"publisher","first-page":"e2400477","DOI":"10.1200\/PO-24-00477","volume":"8","author":"FP Worden","year":"2024","unstructured":"Worden, F. P. et al. Palbociclib in patients with head and neck cancer and other tumors with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis. Oncol. 8, e2400477 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"2954_CR465","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105498","volume":"10","author":"M-V Teleanu","year":"2025","unstructured":"Teleanu, M.-V. et al. CDK4\/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial. ESMO Open 10, 105498 (2025).","journal-title":"ESMO Open"},{"key":"2954_CR466","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 37, 1169\u20131178 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR467","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.01.184","volume":"118","author":"S Sheth","year":"2024","unstructured":"Sheth, S. et al. Phase II trial of abemaciclib in unresectable or metastatic anaplastic thyroid cancer. Int. J. Radiat. Oncol. Biol. Phys. 118, e83 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2954_CR468","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","volume":"23","author":"DA Fennell","year":"2022","unstructured":"Fennell, D. A. et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 23, 374\u2013381 (2022).","journal-title":"Lancet Oncol."},{"key":"2954_CR469","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2024.42.3_suppl.308","volume":"42","author":"T Al Baghdadi","year":"2024","unstructured":"Al Baghdadi, T. et al. Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J. Clin. Oncol. 42, 308 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR470","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1200\/JCO.2023.41.16_suppl.6044","volume":"41","author":"J Fayette","year":"2023","unstructured":"Fayette, J. et al. Abemaciclib in recurrent\/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and\/or CCND1 and\/or CDK6 amplification: A phase II multicenter trial. J. Clin. Oncol. 41, 6044 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR471","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2019.37.15_suppl.2038","volume":"37","author":"JM Sepulveda-Sanchez","year":"2019","unstructured":"Sepulveda-Sanchez, J. M. et al. Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: a Spanish group for research in neurooncology (GEINO) trial. J. Clin. Oncol. 37, 3028 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR472","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1078-0432.CCR-24-2647","volume":"31","author":"S Goel","year":"2025","unstructured":"Goel, S. et al. A phase II study of abemaciclib for patients with retinoblastoma-positive, metastatic triple-negative breast cancer. Clin. Cancer Res. 31, 1427\u20131436 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR473","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1200\/JCO.2025.43.16_suppl.5514","volume":"43","author":"S Damian","year":"2025","unstructured":"Damian, S. et al. Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC). J. Clin. Oncol. 43, 5514 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR474","doi-asserted-by":"publisher","first-page":"25277","DOI":"10.1074\/jbc.C300126200","volume":"278","author":"H Nakojima","year":"2003","unstructured":"Nakojima, H., Toyoshima-Morimoto, F., Taniguchi, E. & Nishida, E. Identification of a consensus motif for PlK (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J. Biol. Chem. 278, 25277\u201325280 (2003).","journal-title":"J. Biol. Chem."},{"key":"2954_CR475","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/onc.2016.347","volume":"36","author":"W Bruinsma","year":"2017","unstructured":"Bruinsma, W. et al. Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora. Oncogene 36, 1840\u20131848 (2017).","journal-title":"Oncogene"},{"key":"2954_CR476","doi-asserted-by":"publisher","first-page":"BR237","DOI":"10.12659\/MSM.882900","volume":"18","author":"DP Han","year":"2012","unstructured":"Han, D. P. et al. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med. Sci. Monit. 18, BR237\u2013BR246 (2012).","journal-title":"Med. Sci. Monit."},{"key":"2954_CR477","doi-asserted-by":"publisher","first-page":"705745","DOI":"10.1155\/2015\/705745","volume":"2015","author":"S Kumar","year":"2015","unstructured":"Kumar, S. & Kim, J. PLK-1 targeted inhibitors and their potential against tumorigenesis. BioMed. Res. Int. 2015, 705745 (2015).","journal-title":"BioMed. Res. Int."},{"key":"2954_CR478","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.4155\/fmc.13.166","volume":"5","author":"V Maluf","year":"2015","unstructured":"Maluf, V., Andricopulo, A. D., Oliva, G. & Guido, R. V. A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors. Future Med. Chem. 5, 2019\u20132035 (2015).","journal-title":"Future Med. Chem."},{"key":"2954_CR479","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","volume":"137","author":"J Luo","year":"2009","unstructured":"Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835\u2013848 (2009).","journal-title":"Cell"},{"key":"2954_CR480","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1158\/1078-0432.CCR-18-3516","volume":"25","author":"S Carbajosa","year":"2019","unstructured":"Carbajosa, S. et al. Polo-like kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction. Clin. Cancer Res. 25, 4049\u20134062 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR481","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17697-1","volume":"11","author":"E Montaudon","year":"2020","unstructured":"Montaudon, E. et al. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat. Commun. 11, 4053 (2020).","journal-title":"Nat. Commun."},{"key":"2954_CR482","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.7150\/thno.63416","volume":"11","author":"C Yang","year":"2021","unstructured":"Yang, C. et al. Mapping the landscape of synthetic lethal interactions in liver cancer. Theranostics 11, 9038\u20139053 (2021).","journal-title":"Theranostics"},{"key":"2954_CR483","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1158\/1535-7163.MCT-18-0177","volume":"17","author":"F Higuchi","year":"2018","unstructured":"Higuchi, F. et al. PLk1 inhibition targets MYC-activated malignant glioma cells irrespective of mismatch repair deficiency\u2013mediated acquired resistance to temozolomide. Mol. Cancer Ther. 17, 2551\u20132563 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2954_CR484","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2767-9764.CRC-24-0260","volume":"5","author":"AS Sheth","year":"2025","unstructured":"Sheth, A. S. et al. PLK1 inhibition induces synthetic lethality in Fanconi anemia pathway\u2013deficient acute myeloid leukemia. Cancer Res. Commun. 5, 648\u2013667 (2025).","journal-title":"Cancer Res. Commun."},{"key":"2954_CR485","unstructured":"Cardiff Oncology, Inc. Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer. PR Newswire https:\/\/www.prnewswire.com\/news-releases\/cardiff-oncology-announces-fast-track-designation-granted-by-the-fda-to-onvansertib-for-second-line-treatment-of-kras-mutated-colorectal-cancer-301066789.html (2025)."},{"key":"2954_CR486","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO-24-01266","volume":"43","author":"DH Ahn","year":"2024","unstructured":"Ahn, D. H. et al. Onvansertib in combination with chemotherapy and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: a single-arm, phase II trial. J. Clin. Oncol. 43, 840\u2013851 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR487","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trecan.2020.09.007","volume":"7","author":"A Schrempf","year":"2021","unstructured":"Schrempf, A., Slyskova, J. & Loizou, J. I. Targeting the DNA repair enzyme polymerase \u03b8 in cancer therapy. Trends Cancer 7, 98\u2013111 (2021).","journal-title":"Trends Cancer"},{"key":"2954_CR488","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2012.29","volume":"1","author":"C Allera-Moreau","year":"2012","unstructured":"Allera-Moreau, C. et al. DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early\/mid-stage non-small cell lung cancer patients. Oncogenesis 1, e30 (2012).","journal-title":"Oncogenesis"},{"key":"2954_CR489","doi-asserted-by":"publisher","first-page":"13390","DOI":"10.1073\/pnas.0910759107","volume":"107","author":"F Lem\u00e9e","year":"2010","unstructured":"Lem\u00e9e, F. et al. DNA polymerase \u03b8 up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc. Natl. Acad. Sci. USA 107, 13390\u201313395 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2954_CR490","doi-asserted-by":"publisher","first-page":"10381","DOI":"10.1128\/MCB.24.23.10381-10389.2004","volume":"24","author":"N Shima","year":"2004","unstructured":"Shima, N., Munroe, R. J. & Schimenti, J. C. The mouse genomic instability mutation chaos1 is an allele of Polq that exhibits genetic interaction with Atm. Mol. Cell. Biol. 24, 10381\u201310389 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"2954_CR491","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.molcel.2016.06.020","volume":"63","author":"DW Wyatt","year":"2016","unstructured":"Wyatt, D. W. et al. Essential roles for polymerase \u03b8-mediated end joining in the repair of chromosome breaks. Mol. Cell 63, 662\u2013673 (2016).","journal-title":"Mol. Cell"},{"key":"2954_CR492","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1074\/jbc.RA118.005188","volume":"294","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. DNA polymerase (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse. J. Biol. Chem. 294, 3909\u20133919 (2019).","journal-title":"J. Biol. Chem."},{"key":"2954_CR493","doi-asserted-by":"publisher","first-page":"e1008319","DOI":"10.1371\/journal.pgen.1008319","volume":"15","author":"AA Kelso","year":"2019","unstructured":"Kelso, A. A., Lopezcolorado, F. W., Bhargava, R. & Stark, J. M. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response. PLoS Genet. 15, e1008319 (2019).","journal-title":"PLoS Genet."},{"key":"2954_CR494","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.str.2015.10.014","volume":"23","author":"JA Newman","year":"2015","unstructured":"Newman, J. A., Cooper, C. D. O., Aitkenhead, H. & Gileadi, O. Structure of the helicase domain of DNA polymerase theta reveals a possible role in the microhomology-mediated end-joining pathway. Structure 23, 2319\u20132330 (2015).","journal-title":"Structure"},{"key":"2954_CR495","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/nsmb.2993","volume":"22","author":"KE Zahn","year":"2015","unstructured":"Zahn, K. E., Averill, A. M., Aller, P., Wood, R. D. & Doubli\u00e9, S. Human DNA polymerase \u03b8 grasps the primer terminus to mediate DNA repair. Nat. Struct. Mol. Biol. 22, 304\u2013311 (2015).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2954_CR496","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","volume":"3","author":"JE Jaspers","year":"2013","unstructured":"Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors. Cancer Discov. 3, 68\u201381 (2013).","journal-title":"Cancer Discov."},{"key":"2954_CR497","doi-asserted-by":"publisher","first-page":"S566","DOI":"10.1016\/j.annonc.2025.08.1493","volume":"36","author":"TA Yap","year":"2025","unstructured":"Yap, T. A. et al. 924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors. Ann. Oncol. 36, S566\u2013S567 (2025).","journal-title":"Ann. Oncol."},{"key":"2954_CR498","doi-asserted-by":"publisher","first-page":"CT152","DOI":"10.1158\/1538-7445.AM2025-CT152","volume":"85","author":"Y Du","year":"2025","unstructured":"Du, Y. et al. Abstract CT152: a phase I study of POLQ inhibitor SYN818 as monotherapy in adult patients with locally advanced or metastatic solid tumors. Cancer Res. 85, CT152 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR499","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","volume":"17","author":"SMB Nijman","year":"2005","unstructured":"Nijman, S. M. B. et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331\u2013339 (2005).","journal-title":"Mol. Cell"},{"key":"2954_CR500","doi-asserted-by":"publisher","first-page":"10362","DOI":"10.1074\/jbc.M109.092544","volume":"285","author":"KY Lee","year":"2010","unstructured":"Lee, K. Y. et al. Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through its interactions with PCNA and USP1. J. Biol. Chem. 285, 10362\u201310369 (2010).","journal-title":"J. Biol. Chem."},{"key":"2954_CR501","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.devcel.2009.01.001","volume":"16","author":"JM Kim","year":"2009","unstructured":"Kim, J. M. et al. Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev. Cell 16, 314\u2013320 (2009).","journal-title":"Dev. Cell"},{"key":"2954_CR502","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3389\/fonc.2019.01406","volume":"9","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. Inhibition of ubiquitin specific protease 1 sensitizes colorectal cancer cells to DNA-damaging chemotherapeutics. Front. Oncol. 9, 1406 (2019).","journal-title":"Front. Oncol."},{"key":"2954_CR503","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nchembio.1455","volume":"10","author":"Q Liang","year":"2014","unstructured":"Liang, Q. et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat. Chem. Biol. 10, 298\u2013304 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"2954_CR504","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","volume":"84","author":"L Cadzow","year":"2024","unstructured":"Cadzow, L. et al. The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination\u2013deficient tumors. Cancer Res. 84, 3419\u20133434 (2024).","journal-title":"Cancer Res."},{"key":"2954_CR505","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0959-8049(20)31087-X","volume":"138","author":"P Sullivan","year":"2020","unstructured":"Sullivan, P. et al. USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors. Eur. J. Cancer 138, S7\u2013S8 (2020).","journal-title":"Eur. J. Cancer"},{"key":"2954_CR506","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/1538-7445.AM2023-502","volume":"83","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Abstract 502: ISM3091, a novel selective USP1 inhibitor as a targeted anticancer therapy. Cancer Res. 83, 502 (2023).","journal-title":"Cancer Res."},{"key":"2954_CR507","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nature10515","volume":"479","author":"V Garcia","year":"2011","unstructured":"Garcia, V., Phelps, S. E. L., Gray, S. & Neale, M. J. Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1. Nature 479, 241\u2013244 (2011).","journal-title":"Nature"},{"key":"2954_CR508","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature24060","volume":"550","author":"W Zhao","year":"2017","unstructured":"Zhao, W. et al. Promotion of RAD51-mediated homologous DNA pairing by BRCA1-BARD1. Nature 550, 360\u2013365 (2017).","journal-title":"Nature"},{"key":"2954_CR509","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.molcel.2019.01.005","volume":"73","author":"A Piazza","year":"2019","unstructured":"Piazza, A. et al. Dynamic processing of displacement loops during recombinational DNA repair. Mol. Cell 73, 1255\u20131266.e4 (2019).","journal-title":"Mol. Cell"},{"key":"2954_CR510","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1365-2559.2009.03448.x","volume":"55","author":"A Mitra","year":"2009","unstructured":"Mitra, A. et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 55, 696\u2013704 (2009).","journal-title":"Histopathology"},{"key":"2954_CR511","first-page":"219","volume":"62","author":"E Raderschall","year":"2002","unstructured":"Raderschall, E. et al. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 62, 219\u2013225 (2002).","journal-title":"Cancer Res."},{"key":"2954_CR512","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03071-w","volume":"23","author":"YF Tsai","year":"2023","unstructured":"Tsai, Y. F. et al. RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. Cancer Cell Int. 23, 231 (2023).","journal-title":"Cancer Cell Int."},{"key":"2954_CR513","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.22738","volume":"121","author":"T Takenaka","year":"2007","unstructured":"Takenaka, T. et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int. J. Cancer 121, 895\u2013900 (2007).","journal-title":"Int. J. Cancer"},{"key":"2954_CR514","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2022.40.16_suppl.3084","volume":"40","author":"RC Lynch","year":"2022","unstructured":"Lynch, R. C. et al. Phase 1 results of a phase 1\/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. J. Clin. Oncol. 40, 3084 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR515","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ijc.35164","volume":"156","author":"J Mann","year":"2025","unstructured":"Mann, J. et al. Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. Int. J. Cancer 156, 389\u2013402 (2025).","journal-title":"Int. J. Cancer"},{"key":"2954_CR516","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/genes12060920","volume":"12","author":"IS Shkundina","year":"2021","unstructured":"Shkundina, I. S., Gall, A. A., Dick, A., Cocklin, S. & Mazin, A. V. New rad51 inhibitors to target homologous recombination in human cells. Genes 12, 920 (2021).","journal-title":"Genes"},{"key":"2954_CR517","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1016\/j.bmcl.2017.05.039","volume":"27","author":"A Ward","year":"2017","unstructured":"Ward, A. et al. Quinazolinone derivatives as inhibitors of homologous recombinase RAD51. Bioorg. Med. Chem. Lett. 27, 3096\u20133100 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2954_CR518","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.1016\/j.annonc.2023.09.1537","volume":"34","author":"S Patra","year":"2023","unstructured":"Patra, S. et al. 35P SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models. Ann. Oncol. 34, S197 (2023).","journal-title":"Ann. Oncol."},{"key":"2954_CR519","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1538-7445.AM2022-5441","volume":"82","author":"P Gu","year":"2022","unstructured":"Gu, P. et al. Abstract 5441: Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer. Cancer Res. 82, 5441 (2022).","journal-title":"Cancer Res."},{"key":"2954_CR520","doi-asserted-by":"publisher","first-page":"147","DOI":"10.20517\/jtgg.2021.60","volume":"6","author":"P Gupta","year":"2022","unstructured":"Gupta, P., Majumdar, A. G. & Patro, B. S. Enigmatic role of WRN-RECQL helicase in DNA repair and its implications in cancer. J. Transl. Genet. Genom. 6, 147\u2013156 (2022).","journal-title":"J. Transl. Genet. Genom."},{"key":"2954_CR521","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.dnarep.2009.12.011","volume":"9","author":"ML Rossi","year":"2010","unstructured":"Rossi, M. L., Ghosh, A. K. & Bohr, V. A. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair 9, 331\u2013344 (2010).","journal-title":"DNA Repair"},{"key":"2954_CR522","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","volume":"568","author":"EM Chan","year":"2019","unstructured":"Chan, E. M. et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 551\u2013556 (2019).","journal-title":"Nature"},{"key":"2954_CR523","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022111998","volume":"42","author":"V Mengoli","year":"2023","unstructured":"Mengoli, V. et al. WRN helicase and mismatch repair complexes independently and synergistically disrupt cruciform DNA structures. EMBO J. 42, e111998 (2023).","journal-title":"EMBO J."},{"key":"2954_CR524","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","volume":"629","author":"S Ferretti","year":"2024","unstructured":"Ferretti, S. et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature 629, 443\u2013449 (2024).","journal-title":"Nature"},{"key":"2954_CR525","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","volume":"629","author":"KA Baltgalvis","year":"2024","unstructured":"Baltgalvis, K. A. et al. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature 629, 435\u2013442 (2024).","journal-title":"Nature"},{"key":"2954_CR526","doi-asserted-by":"publisher","first-page":"CT016","DOI":"10.1158\/1538-7445.AM2025-CT016","volume":"85","author":"TA Yap","year":"2025","unstructured":"Yap, T. A. et al. Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and\/or mismatch repair deficient (dMMR) advanced solid tumors. Cancer Res. 85, CT016 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR527","doi-asserted-by":"publisher","first-page":"e47462","DOI":"10.1371\/journal.pone.0047462","volume":"7","author":"AA Cardoso","year":"2012","unstructured":"Cardoso, A. A. et al. APE1\/Ref-1 Regulates STAT3 Transcriptional Activity and APE1\/Ref-1-STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival. PLoS ONE 7, e47462 (2012).","journal-title":"PLoS ONE"},{"key":"2954_CR528","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1093\/nar\/gkn416","volume":"36","author":"K Ando","year":"2008","unstructured":"Ando, K. et al. A new APE1\/Ref-1-dependent pathway leading to reduction of NF-\u03baB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 36, 4327\u20134336 (2008).","journal-title":"Nucleic Acids Res."},{"key":"2954_CR529","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.lungcan.2007.10.015","volume":"60","author":"DG Yoo","year":"2008","unstructured":"Yoo, D. G. et al. Alteration of APE1\/ref-1 expression in non-small cell lung cancer: The implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer 60, 277\u2013284 (2008).","journal-title":"Lung Cancer"},{"key":"2954_CR530","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/07357907.2010.512816","volume":"28","author":"Y Jiang","year":"2010","unstructured":"Jiang, Y., Zhou, S., Sandusky, G. E., Kelley, M. R. & Fishel, M. L. Reduced expression of DNA repair and redox signaling protein APE1\/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest. 28, 885\u2013895 (2010).","journal-title":"Cancer Invest."},{"key":"2954_CR531","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2019.37.15_suppl.3097","volume":"37","author":"S Shahda","year":"2019","unstructured":"Shahda, S. et al. A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors. J. Clin. Oncol. 37, 3097 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR532","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1089\/ars.2008.2120","volume":"10","author":"M Luo","year":"2008","unstructured":"Luo, M. et al. Role of the multifunctional DNA repair and redox signaling protein Ape1\/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid. Redox Signal. 10, 1853\u20131867 (2008).","journal-title":"Antioxid. Redox Signal."},{"key":"2954_CR533","doi-asserted-by":"publisher","first-page":"9055","DOI":"10.1200\/JCO.2020.38.15_suppl.9055","volume":"38","author":"M Koczywas","year":"2020","unstructured":"Koczywas, M. et al. Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors\/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin. J. Clin. Oncol. 38, 9055 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR534","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1200\/JCO.2023.41.16_suppl.5564","volume":"41","author":"S Shin","year":"2023","unstructured":"Shin, S. et al. Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer. J. Clin. Oncol. 41, 5564 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR535","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.medj.2023.12.009","volume":"5","author":"AA Sch\u00e4ffer","year":"2024","unstructured":"Sch\u00e4ffer, A. A., Chung, Y., Kammula, A. V., Ruppin, E. & Lee, J. S. A systematic analysis of the landscape of synthetic lethality-driven precision oncology. Med 5, 73\u201389.e9 (2024).","journal-title":"Med"},{"key":"2954_CR536","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"2954_CR537","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807\u20131812 (2008).","journal-title":"Science"},{"key":"2954_CR538","doi-asserted-by":"publisher","first-page":"105492","DOI":"10.1016\/j.jbc.2023.105492","volume":"300","author":"GT Bedard","year":"2024","unstructured":"Bedard, G. T. et al. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition. J. Biol. Chem. 300, 105492 (2024).","journal-title":"J. Biol. Chem."},{"key":"2954_CR539","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41420-025-02545-2","volume":"11","author":"Z Jiang","year":"2025","unstructured":"Jiang, Z. et al. Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models. Cell Death Discov. 11, 261 (2025).","journal-title":"Cell Death Discov."},{"key":"2954_CR540","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","volume":"15","author":"K Marjon","year":"2016","unstructured":"Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis. Cell Rep. 15, 574\u2013587 (2016).","journal-title":"Cell Rep."},{"key":"2954_CR541","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/cam4.2114","volume":"8","author":"M Vinet","year":"2019","unstructured":"Vinet, M. et al. Protein arginine methyltransferase 5: a novel therapeutic target for triple-negative breast cancers. Cancer Med. 8, 2414\u20132428 (2019).","journal-title":"Cancer Med."},{"key":"2954_CR542","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/leu.2017.206","volume":"32","author":"S Kaushik","year":"2018","unstructured":"Kaushik, S. et al. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. Leukemia 32, 499\u2013509 (2018).","journal-title":"Leukemia"},{"key":"2954_CR543","doi-asserted-by":"publisher","first-page":"204062072412753","DOI":"10.1177\/20406207241275376","volume":"15","author":"J Watts","year":"2024","unstructured":"Watts, J. et al. Phase I\/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms. Ther. Adv. Hematol. 15, 20406207241275376 (2024).","journal-title":"Ther. Adv. Hematol."},{"key":"2954_CR544","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.annonc.2025.08.3757","volume":"36","author":"MM Gounder","year":"2025","unstructured":"Gounder, M. M. et al. Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers. Ann. Oncol. 36, 1480\u20131491 (2025).","journal-title":"Ann. Oncol."},{"key":"2954_CR545","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/JCO.2025.43.16_suppl.3011","volume":"43","author":"KC Arbour","year":"2025","unstructured":"Arbour, K. C. et al. BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007. J. Clin. Oncol. 43, 3011 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR546","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jtho.2025.09.054","volume":"20","author":"P Janne","year":"2025","unstructured":"Janne, P. et al. OA08.01 BMS-986504 in patients with homozygous MTAP-Deletion (Del): clinical results in patients with NSCLC enrolled in CA240-0007. J. Thorac. Oncol. 20, S25\u2013S26 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"2954_CR547","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon, J. et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann. Oncol. 35, 1138\u20131147 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR548","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","volume":"39","author":"P Kalev","year":"2021","unstructured":"Kalev, P. et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell 39, 209\u2013224.e11 (2021).","journal-title":"Cancer Cell"},{"key":"2954_CR549","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55316-5","volume":"16","author":"M Gounder","year":"2025","unstructured":"Gounder, M. et al. MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial. Nat. Commun. 16, 423 (2025).","journal-title":"Nat. Commun."},{"key":"2954_CR550","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/ng.2628","volume":"45","author":"C Kadoch","year":"2013","unstructured":"Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592\u2013601 (2013).","journal-title":"Nat. Genet."},{"key":"2954_CR551","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/MCB.01372-13","volume":"34","author":"BG Wilson","year":"2014","unstructured":"Wilson, B. G. et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol. Cell. Biol. 34, 1136\u20131144 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"2954_CR552","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","volume":"175","author":"N Mashtalir","year":"2018","unstructured":"Mashtalir, N. et al. Modular organization and assembly of SWI\/SNF family chromatin remodeling complexes. Cell 175, 1272\u20131288.e20 (2018).","journal-title":"Cell"},{"key":"2954_CR553","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nm.3480","volume":"20","author":"KC Helming","year":"2014","unstructured":"Helming, K. C. et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20, 251\u2013254 (2014).","journal-title":"Nat. Med."},{"key":"2954_CR554","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","volume":"73","author":"T Oike","year":"2013","unstructured":"Oike, T. et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 73, 5508\u20135518 (2013).","journal-title":"Cancer Res."},{"key":"2954_CR555","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/s41588-019-0477-9","volume":"51","author":"S Schick","year":"2019","unstructured":"Schick, S. et al. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nat. Genet. 51, 1399\u20131410 (2019).","journal-title":"Nat. Genet."},{"key":"2954_CR556","doi-asserted-by":"publisher","first-page":"S483","DOI":"10.1016\/j.annonc.2024.08.670","volume":"35","author":"R Guo","year":"2024","unstructured":"Guo, R. et al. 603O First clinical results from a phase I trial of PRT3789: a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation. Ann. Oncol. 35, S483\u2013S484 (2024).","journal-title":"Ann. Oncol."},{"key":"2954_CR557","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1158\/1538-7445.AM2025-3779","volume":"85","author":"NA Brooks","year":"2025","unstructured":"Brooks, N. A. et al. Abstract 3779: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors. Cancer Res. 85, 3779 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR558","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1021\/acs.jmedchem.4c02535","volume":"68","author":"RG Vaswani","year":"2025","unstructured":"Vaswani, R. G. et al. Discovery of FHD-286, a first-in-class, orally bioavailable, allosteric dual inhibitor of the Brahma homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase activity for the treatment of SWItch\/sucrose non-fermentable (SWI\/SNF) dependent cancers. J. Med. Chem. 68, 1772\u20131792 (2025).","journal-title":"J. Med. Chem."},{"key":"2954_CR559","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-24-3790","volume":"31","author":"CD DiNardo","year":"2025","unstructured":"DiNardo, C. D. et al. A phase I study of FHD-286, a dual BRG1\/BRM (SMARCA4\/SMARCA2) inhibitor, in patients with advanced myeloid malignancies. Clin. Cancer Res. 31, 2327\u20132338 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2954_CR560","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler, B. G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231\u2013238 (2015).","journal-title":"Nat. Med."},{"key":"2954_CR561","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1200\/JCO.2022.40.16_suppl.10040","volume":"40","author":"SN Chi","year":"2022","unstructured":"Chi, S. N. et al. Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1\u2013negative tumors. J. Clin. Oncol. 40, 10040 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR562","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.1200\/JCO.2022.40.16_suppl.10009","volume":"40","author":"SN Chi","year":"2025","unstructured":"Chi, S. N. et al. Tazemetostat in patients with tumors with alterations in EZH2 or the SWI\/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C). J. Clin. Oncol. 40, 10009 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR563","doi-asserted-by":"publisher","first-page":"VIII580","DOI":"10.1093\/annonc\/mdy299.010","volume":"29","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti, S. et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Ann. Oncol. 29, VIII580\u2013VIII581 (2018).","journal-title":"Ann. Oncol."},{"key":"2954_CR564","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-24-0398","volume":"84","author":"PJ Keller","year":"2024","unstructured":"Keller, P. J. et al. Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers. Cancer Res. 84, 2501\u20132517 (2024).","journal-title":"Cancer Res."},{"key":"2954_CR565","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO.2025.43.16_suppl.3102","volume":"43","author":"LR Duska","year":"2025","unstructured":"Duska, L. R. et al. Phase II dose optimization update with EZH2\/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma or endometrial carcinoma. J. Clin. Oncol. 43, 3102 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2954_CR566","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1091\/mbc.E16-05-0269","volume":"27","author":"H Sellou","year":"2016","unstructured":"Sellou, H. et al. The poly(ADP-ribose)-dependent chromatin remodeler Alc1 induces local chromatin relaxation upon DNA damage. Mol. Biol. Cell 27, 3791\u20133799 (2016).","journal-title":"Mol. Biol. Cell"},{"key":"2954_CR567","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.molcel.2020.12.006","volume":"81","author":"G Hewitt","year":"2021","unstructured":"Hewitt, G. et al. Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. Mol. Cell 81, 767\u2013783.e11 (2021).","journal-title":"Mol. Cell"},{"key":"2954_CR568","doi-asserted-by":"publisher","first-page":"FSO650","DOI":"10.2144\/fsoa-2020-0140","volume":"7","author":"C Gulliver","year":"2021","unstructured":"Gulliver, C., Hoffmann, R. & Baillie, G. S. The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Sci. OA 7, FSO650 (2021).","journal-title":"Future Sci. OA"},{"key":"2954_CR569","doi-asserted-by":"publisher","first-page":"8261","DOI":"10.1007\/s00018-021-04013-3","volume":"78","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. DHX9 contributes to the malignant phenotypes of colorectal cancer via activating NF-\u03baB signaling pathway. Cell. Mol. Life Sci. 78, 8261\u20138281 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"2954_CR570","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-24-0397","volume":"85","author":"J Castro","year":"2025","unstructured":"Castro, J. et al. A Potent, Selective, Small-molecule Inhibitor of DHX9 abrogates proliferation of microsatellite instable cancers with deficient mismatch repair. Cancer Res. 85, 758\u2013776 (2025).","journal-title":"Cancer Res."},{"key":"2954_CR571","doi-asserted-by":"publisher","first-page":"PR003","DOI":"10.1158\/1538-7445.DNAREPAIR24-PR003","volume":"84","author":"J Castro","year":"2024","unstructured":"Castro, J. et al. Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2. Cancer Res. 84, PR003 (2024).","journal-title":"Cancer Res."},{"key":"2954_CR572","unstructured":"Adams, B. AstraZeneca and Merck\u2019s Lynparza set to \u2018dominate\u2019 PARP market as it looks to grow cancer offerings with 100-plus ongoing trials. FIERCE Pharma https:\/\/www.fiercepharma.com\/marketing\/astrazeneca-and-mercks-lynparza-set-dominate-parp-market-it-looks-grow-cancer-offerings# (2024)."},{"key":"2954_CR573","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726 (2020).","journal-title":"Nat. Commun."},{"key":"2954_CR574","doi-asserted-by":"publisher","first-page":"150517","DOI":"10.1016\/j.bbrc.2024.150517","volume":"738","author":"TA Kato","year":"2024","unstructured":"Kato, T. A., Maeda, J., Watanabe, H., Kawamura, S. & Wilson, P. F. Simultaneous inhibition of ATM, ATR, and DNA-PK causes synergistic lethality. Biochem. Biophys. Res. Commun. 738, 150517 (2024).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2954_CR575","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1038\/s41388-025-03343-x","volume":"44","author":"M Hofstad","year":"2025","unstructured":"Hofstad, M. et al. Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer. Oncogene 44, 1746\u20131760 (2025).","journal-title":"Oncogene"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02954-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02954-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02954-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:03:54Z","timestamp":1790172234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02954-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":575,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02954-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jordi Surrall\u00e9s has signed agreements (advisory boards, service provision, research collaboration or material transfer) in the last 3 years with Boehringer Ingelheim, Glaxo Smith Kline, Moderna Therapeutics, Roche, Rocket Pharmaceuticals and Pfizer. Jordi Surrall\u00e9s and Jordi Minguill\u00f3n have a patent repurposing of afatinib issued to IR Sant Pau, UAB and CIBER. Cristina Camps-Fajol declares that she has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"403"}}